A Review of the Recent Advances in Alzheimer’s Disease Research and the Utilization of Network Biology Approaches for Prioritizing Diagnostics and Therapeutics

Rima Hajjo 1,2,3,*, Dima A. Sabbah 1, Osama H. Abusara 1 and Abdel Qader Al Bawab 1

1 Department of Pharmacy, Faculty of Pharmacy, Al-Zaytoonah University of Jordan, P.O. Box 130, Amman 11733, Jordan
2 Laboratory for Molecular Modeling, Division of Chemical Biology and Medicinal Chemistry, Eshelman School of Pharmacy, The University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA
3 National Center for Epidemics and Communicable Disease Control, Amman 11118, Jordan
* Correspondence: r.hajjo@zuj.edu.jo

Abstract: Alzheimer’s disease (AD) is a polygenic multifactorial neurodegenerative disease that, after decades of research and development, is still without a cure. There are some symptomatic treatments to manage the psychological symptoms but none of these drugs can halt disease progression. Additionally, over the last few years, many anti-AD drugs failed in late stages of clinical trials and many hypotheses surfaced to explain these failures, including the lack of clear understanding of disease pathways and processes. Recently, different epigenetic factors have been implicated in AD pathogenesis; thus, they could serve as promising AD diagnostic biomarkers. Additionally, network biology approaches have been suggested as effective tools to study AD on the systems level and discover multi-target-directed ligands as novel treatments for AD. Herein, we provide a comprehensive review on Alzheimer’s disease pathophysiology to provide a better understanding of disease pathogenesis hypotheses and decipher the role of genetic and epigenetic factors in disease development and progression. We also provide an overview of disease biomarkers and drug targets and suggest network biology approaches as new tools for identifying novel biomarkers and drugs. We also posit that the application of machine learning and artificial intelligence to mining Alzheimer’s disease multi-omics data will facilitate drug and biomarker discovery efforts and lead to effective individualized anti-Alzheimer treatments.

Keywords: Alzheimer’s disease (AD); diagnostic biomarkers; drug prioritization; epigenetics; network biology; multi-target drug ligands (MTDLs); disease pathways

1. Introduction

Alzheimer’s disease (AD) is a polygenic and multifactorial disease characterized by the deposition of amyloid-β (Aβ) fibrils in the brain, leading to the formation of plaques and neurofibrillary tangles (NFTs), and ultimately resulting in dendritic dysfunction, neuronal cell death, memory loss, behavioral changes, and organ shutdown [1–5]. It is estimated that 6.5 million Americans, 65 years and older, are living with Alzheimer’s dementia, and this number is likely to grow rapidly [6], reaching 13.8 million by 2060 [6,7]. Additionally, approximately 10 million Americans are currently living with mild cognitive impairment (MCI). In fact, 50% of MCI cases are due to AD based on biomarker evidence [8]. Eventually, 15% of MCI patients develop dementia after two years, and one-third develop dementia due to AD within five years [6]. The number of Americans with AD-MCI and AD dementia is approximately 11.2 million [6]. The healthcare cost for AD patients in 2022 is expected to reach USD 321 billion [6]. Furthermore, as the global population ages, the number of people suffering from dementia is expected to triple from 50 million to 152 million by 2050 [9]. Therefore, there is an urgent need to impede or slow down the onset and progress of the
disease and ameliorate the disease-debilitating symptoms in hopes of putting an end to this disease and preventing a growing public health crisis [10].

Multifactorial mechanisms are involved in AD pathogenesis, including genetic, epigenetic, biological, and environmental factors networking with each other [11]. However, genomic experiments affirmed that no particular gene could be assigned as a potential target for AD pathogenesis. In fact, multiple genetic and non-genetic factors contribute to disease development [11–18]. In the past decade, there has been an increased understanding of potential targets for disease-modifying therapies that delayed or slowed down the clinical course of AD. According to the U.S. National Library of Medicine’s (NLM) ClinicalTrials.gov Beta (beta.clinicaltrials.gov) [19], there have been 1943 clinical trials of different phases and different designs to investigate new potential molecules in treating AD. Among these studies, 151 clinical trials progressed to Phase III clinical trials, in which safety and monitoring of side effects were investigated.

After decades of AD drug discovery research and billions of dollars spent on clinical trials, we still do not have a single effective anti-AD drug. Promising novel strategies to developing anti-AD drugs keep failing in clinical trials [20,21]. The exact cause of the disease remains the subject of ongoing debate and investigation. At this time, the most plausible hypothesis is that AD is a multifactorial disorder in which genetic and environmental risk factors interact, leading to an acceleration in the rate of normal aging. More than 600 genes contribute to AD pathogenesis, along with environmental factors and epigenetic changes [4,5]. The genetic deficiencies in AD consist of germline mutations, mitochondrial DNA mutations, and single-DNA nucleotide polymorphisms [22,23].

Therapeutic clinical treatment targets of AD aim to enhance behavioral, cognitive, and non-cognitive symptoms of the diseases. In the last two decades, there were no new medication approvals for the treatment or the prevention of AD. Currently, the aim of developing new anti-AD agents is to utilize new disease-modifying agents that delay the onset or slow down the progression of an established disease. Aβ, tau protein, and cell oxidation are the most currently promising targets to modify the pathologic status of Alzheimer’s disease [24].

In this review, we aim to provide a comprehensive overview of AD pathophysiological hypotheses, classifications, diagnostic biomarkers, and currently approved pharmacological and non-pharmacological treatment options. Moreover, we discuss the emerging role of the microbiome as well as epigenetics in the pathogenesis of AD and discuss the potential of epigenetic and genetic treatment options. We also provide a summary on drugs being developed or currently investigated in clinical trials, their success, failures or drawbacks, newer target approaches, and most important considerations for conducting effective future clinical trials. In addition, we discuss novel approaches for the proper diagnosis and drug-development for AD through exploiting network biology, artificial intelligence (AI), and machine learning (ML).

2. Alzheimer’s Disease Pathophysiology

There are two main pathological hallmarks of AD: (1) the presence of increased extracellular Aβ plaques, formed due to the aggregation and impaired clearance of Aβ oligomers (hydrophobic Aβ aggregates) [25,26], and (2) the formation of NFTs [27] that are composed of an insoluble intracellular hyperphosphorylated microtubule-associated protein tau [28–38]. MetaCore’s [39] pathway map presented in Figure 1 summarizes the most important processes, genes, and proteins linked to AD pathophysiology. We further highlighted which network objects on the map that are known AD biomarkers according the MetaCore™, and which ones are drug targets for known drugs (i.e., as a proof of their druggability).
Figure 1. Alzheimer’s disease (AD) pathway map highlighting validated diagnostic/prognostic AD biomarkers in addition to genes/gene products involved in the tau pathology pathway. Connections between network objects on the map are referred to as links (or edges). A link identifies an interaction or a logical relation between two nodes. The type of interaction or relation is reflected by an appropriate symbol placed in the middle of the link. B = binding (i.e., physical interaction between molecules); C = cleavage; CM = covalent modification; +P = phosphorylation; −P = dephosphorylation; Tn = transport; TR = transcription regulation; red arrows = inhibition; green arrows = activation; grey arrows = unspecified action; solid purple arrows = emergence in disease; dashed purple arrows = enhancement in disease; arrows with purple x = disruption in disease; light violet text box = normal process; pink text box = pathological processes; white text box with blue outline = notes; grey block = reaction; blue block = normal process; pink block = pathological process;
2.1. The Amyloid Hypothesis

It was long thought that polymorphism in the amyloid precursor protein (APP) gene (APP) causes alterations within and around the Aβ domain of translated APP proteins, altering APP proteolytic processing, and leading to changes in Aβ cleavage and aggregation [41]. This would favor the amyloidogenic pathway, causing the accumulation of Aβ, which contributes to AD pathogenesis [42].

2.1.1. APP

The APP protein contains the Aβ domain, which, in healthy individuals, is cleaved and processed into Aβ and other Aβ-related peptides [43–49] by a-secretase followed by γ-secretase and later cleared [26,50,51]. The APP protein is encoded by the APP gene (Figure 2), which has 17 transcripts (splice variants), 279 orthologues, 2 paralogues, and is associated with 9 phenotypes (ABeta amyloidosis Arctic type, ABeta amyloidosis Dutch type, ABeta amyloidosis Iowa type, ABeta amyloidosis Italian type, ABetaA21G amyloidosis, ABetaL34V amyloidosis, ADs, cerebral amyloid angiopathy APP-related, and early-onset autosomal dominant AD).

APP genetic variants are often observed in Familial Alzheimer’s disease (FAD) [52–58]. Such mutations in the amino terminus of the Aβ domain result in the production of better substrates for β-secretase (BACE1) activity [55], leading to significant increase in Aβ production and Aβ fragments consisting of 40 or 42 amino acid residues (Aβ40 and Aβ42, respectively) [51,59,60]. These Aβ fragments are formed via the amyloidogenic pathway in AD patients, as BACE1 cleaves APP followed by γ-secretase [50]. Enhanced aggregation of altered Aβ is observed due to mutations affecting the mid region of Aβ [57,58]. Amino acid mutations located beyond the carboxyl terminus region of Aβ increase the production of Aβ42 [55,56], which is considered the major neurotoxic Aβ species [25,42,50,61]. Aβ42 is of particular interest; it is more hydrophobic, more pathogenic, and it aggregates faster than Aβ-40, resulting in an earlier onset of AD.

Furthermore, APP has a substrate inhibitory domain (ASID) that negatively regulates the activity of γ-secretase by decreasing Aβ production [62]. Alterations of ASID region by deletion or single-nucleotide polymorphism were reported, in which an inhibitory effect is reduced, causing an increase in Aβ generation [50,62]. Presenilin (PSEN), the catalytic subunit of γ-secretase [63–66], may also be modified via mutations in PSEN1 and PSEN2 genes (PSEN1 and PSEN2, respectively) [67], resulting in the destabilization of the γ-secretase–APP interactions [68], causing the generation of longer and more hydrophobic Aβ peptides that contribute to the pathogenesis of AD [41,68–70].
Figure 2. Visualizing APP gene information using (a) Ensembl genome browser 107 (July 2022, GRCh38) and (b) NCBI’s gene browser.

2.1.2. Tau

Tau is a microtubule-associated protein, found in axons of neurons [71], and it functions as a microtubule stabilizer that enables cytoplasmic extensions for the eventual formation of the axon and the dendrites [72,73]. Once tau is phosphorylated, its ability to bind to microtubules is reduced [74–77] and self-assembly into tangles/filaments is induced [78], hence affecting its normal function. It is considered as a main pathological lesion in the brains of patients with AD in addition to Aβ fibrils. In fact, AD is considered one of the neurodegenerative diseases that are termed “tauopathies” [79–81], where tauopathy indicates a tau-related pathology (i.e., dysfunction and/or tangle formation that contributes
to the pathogenesis of AD and other neurodegenerative diseases) [27]. As for AD, this is driven by the intracellular aggregation of tau proteins via different mechanisms. Tau’s phosphorylation can lead to aggregation via liquid–liquid phase separation mechanism [82]. Cleavage of tau by several proteases can also lead to aggregation [83–85]. It is also suggested that tau pathology could be a downstream effect of Aβ aggregation or both could enhance each other’s toxic effects [41,86,87]. In vivo, Aβ plaques enhanced the aggregation of human-derived pathological tau injected into mouse brains [88]. In autopsy specimens from deceased AD patients, the number of NFT-positive cells is positively correlated to AD stages [89–93].

2.1.3. APOE, TERM2, SORL1, and ABCA7 Mutations

Mutations of genes, such as apolipoprotein E (APOE) and triggering receptor expressed on myeloid cells 2 (TREM2) [70], would affect the microglial clearance of Aβ. Briefly, APOE protein, which is a lipoprotein, binds to Aβ plaques forming Aβ-lipoprotein complexes that are engulfed into microglia via TREM2 receptors [94]. Mutations of APOE and TREM2, resulting in mutated proteins, such as APOE2, APOE4, or TREM2 mutations (R47H, R62H, and D87N), would contribute to AD development [94–97]. Additionally, genetic mutations of SORL1 and ABCA7 are also considered as causative or strong risk-increasing variants for AD [70]. Sortilin-related receptor L1 (SORL1) controls APP cleavage and APOE uptake, while increasing ATP-binding cassette transporter A7 (ABCA7) increases Aβ phagocytosis [67]. Hence, mutations resulting in alterations of SORL1 and ABCA7 would act as a risk factor for AD [67]. Other genetic mutations that have low, medium, or high risk for AD are summarized by Scheltens et al. [41,70].

2.2. The Cholinergic Hypothesis

In addition to the amyloid hypothesis described above, other hypotheses have been suggested such as the impairment of cholinergic function, also known as the cholinergic hypothesis [98]. The cholinergic deficit in AD patients was confirmed in various studies, which highlighted a major deficit in the enzyme responsible for acetylcholine (ACh) synthesis (choline acetyltransferase) [99–101], reduced choline uptake [102], reduced ACh release [103], and loss of ACh (cholinergic) neurons [104]. Along with the role of ACh in learning and memory [105,106], degeneration of cholinergic neurons and loss of cholinergic neurotransmission contributes to the worsening of cognitive function in patients with AD [106,107].

2.3. The Mitochondrial Cascade (Oxidative Stress) Hypothesis

Neuronal mitochondria are considered the main organelles responsible for the neuronal oxidative stress via the generation of free radicals through their electron transport chain [108]. In the case of high levels of ATP and diminishing electron transport effect, superoxide would be formed from oxygen via mitochondrial respiration [109]. Superoxide would then be converted to hydrogen peroxide by superoxide dismutase and later to hydroxyl radicals and anions by the Fenton reaction [110]. These reactive oxygen species (ROS) would affect redox imbalance, cause neurotoxicity and genomic instability, transcription of pro-inflammatory genes, and cytokine release [111]. ROS would further damage and inactivate parts of the mitochondrial electron transport chain, leading to the formation of superoxide from the electron reduction of oxygen in a positive feedback cycle [109,111,112].

ROS damage mitochondrial DNA (mtDNA) that leads to neuronal functional impairments and damaged mitochondria due to this oxidative stress will not be degraded by mitophagy [108,111,113]. Usually, oxidative stress acts as a signal for mitophagy process to degrade damaged mitochondria, as oxidative stress reduces mitochondrial membrane potential [108]. However, ROS alter parkin, which is a key mitophagy regulator, and inhibits its function, causing the continual presence of mitochondria [113]. Collectively, ROS, DNA damage, and mitochondria contribute to the aging process [114,115]. Briefly, following DNA damage via ROS, kinases and PARP are activated, leading to the decrease
of NAD+ production, which is essential for metabolic pathways and ATP production. Thus, oxygen consumption and ATP production would be required to increase to meet high energy demand. Mitochondrial coupling would occur, which increases membrane potential, increases free radical formation, and decreases mitophagy. Furthermore, as discussed above, free radicals would further cause DNA damage.

Denham Harman proposed the free radical theory of aging, in which free radicals are involved in the changes associated with the aging process [116]. It was later confirmed that free radicals are involved in the aging process and advanced age diseases, such as AD [115,117,118]. Furthermore, the effect of ROS on mitochondria supported the theory that relates mitochondria to the aging process and neurodegenerative diseases, such as AD [108]. This theory is associated mostly with the central nervous system since it consumes 20% of the body’s oxygen and is susceptible to oxidative stress [119]. Neurons would have high sensitivity to free radicals since they are non-dividing and post-mitotic cells and cannot be replaced in the event of damage, leading to mitochondrial dysfunction with aging [118,120].

It is observed that mitochondrial dysfunction is prevalent in the aging process [108]. In addition, healthy aging results in reduced mitochondrial metabolism in terms of α subunit reduction of the mitochondrial F1 ATP synthase, thus interfering with ATP production [108]. Eventually, ATP production decreases, ROS production increase, and this will cause an increase in DNA, protein, and lipid oxidation [118,121,122]. Moreover, apart from mtDNA damage caused by mitochondrial dysfunction, nuclear DNA is also damaged, leading to impairments in vesicular function, synaptic plasticity, and mitochondrial function [121].

Excess ROS and bioactive metals, such as copper, iron, zinc, and magnesium are present in AD brains that promote Aβ aggregations and NFT formation [123–126]. Moreover, the elevated levels of mtDNA oxidation are considered as one of the early markers of AD pathogenesis [118,122]. Moreover, late onset AD pathogenesis may be linked to age-associated mitochondrial decline [108]. The expression and processing of APP would be altered with age-associated mitochondrial decline, leading to the production of Aβ oligomers that aggregate into plaques in AD [127,128]. These Aβ oligomers are associated with neuronal toxicities and ROS generation. Studies have shown that the hydrophobic 25–35 region of Aβ leads to neuronal toxicity and generates ROS, showing that Aβ itself is a source of oxidative stress [108,129,130]. Aβ42 is hydrophobic in nature, and it can reside within the neuronal membrane lipid bilayer and cause lipid peroxidation, identified through 4-hydroxy-2-trans-nonenal (HNE) production that is bound to neuronal proteins [131]. Studies have also shown that the production of HNE—due to lipid peroxidation associated with the residing of hydrophobic Aβ protein in lipid bilayer—and HNE’s neuronal protein binding are linked to cell death [132–134]. These are related to neurodegenerative diseases’ pathogenesis, including AD. Furthermore, the oxidative stress triggered by Aβ is also likely to be as result of complexation with redox active metals, such as copper, zinc, and iron [108], which are highly present in AD brains [123–126], promoting Aβ aggregation into plaques [108]. Copper forms the most stable complex and can generate superoxide and hydrogen peroxide that contribute to AD pathogenesis [127,135].

2.4. Other Factors Affecting Disease Pathogenesis

Other factors that affect the clinical development of AD include vascular pathology of blood–brain barrier that result in leakage and cause dementia [136,137]. Moreover, elevated iron levels in brain and dysregulation of its metabolism are also present in AD patients as it is linked with cellular damage and oxidative stress [138]. Exosomes may play a part in the spreading of Aβ plaques and NFTs through the brain [139].

3. Alzheimer’s Disease Classifications

AD is usually classified on the basis of two criteria: age and heredity (Table 1). Based on age, there are two main forms of AD: late onset AD (LOAD) and early onset AD (EOAD). LOAD is diagnosed at age 65 or older [140], although the degenerative process may begin damaging the brain 20 years before symptoms appear [141]. This is the most prevalent form
of the disease, comprising 95% of patients [142]. Polymorphism in APOE is a major risk determinant of LOAD, contributing to 60–80% of the disease pathogenesis [140,143,144]. APOE encodes for the principal lipid transport protein in the central nervous system (CNS), which has three alleles (E2, E3, and E4). APOE4 surges the risk of LOAD development [11]. Genome-wide association studies (GWAS) identified >20 LOAD risk genes linked to endocytosis, inborn immunity, and lipid metabolism [143,145]. EOAD is typically diagnosed between 40 and 50 years of age, comprises 5% of the total AD cases [146], is linked to a defect in chromosome 14 and myoclonus [147,148], and, therefore, it is referred to as a distinctive autosomal dominant inherited form of AD [140]. Usually, people with Down’s syndrome are more prone to EOAD [149]. In fact, mutations in APP genes, particularly PSEN1 and PSEN2, are associated with EOAD development [140]. These APP variants explain 5–10% of the autosomal dominant inherited cases, leaving the majority of cases totally unexplained [150,151].

Based on heredity, AD can be either familial or sporadic [152]. Compiling the two diagnostic criteria (i.e., age and hereditability), AD can be classified into EOAD, LOAD, early onset familial (eFAD), late-onset familial, early onset sporadic, and late-onset sporadic. Yet, these classifications overlap in terms of nomenclature, diagnosis, and treatment. FAD is linked to genes [153].

Table 1. Main types of Alzheimer’s disease based on age and heredity.

| Classification | Genetic Factors | Age Onset | Clinical Features | Risk Factors | Top Treatments | References |
|----------------|----------------|-----------|------------------|--------------|----------------|------------|
| Early-onset    | Yes            | 40s–50s   | Plaques of amyloid and tau proteins | Family history | Acetylcholinesterase inhibitors (Donepezil, Galantamine, and Rivastigmine) | [154] |
| Late-onset     | Yes (APOE)    | ≥65       | (APOE) ε4 allele | Age ≥ 65 years, genetic and environmental factors | Acetylcholinesterase inhibitors (Donepezil, Galantamine, and Rivastigmine) and treatment of vascular risk factors and sleep and mood disorders | [155] |
| Familial       | Yes (PSEN1, PSEN2, APP) | 40s–50s   | Mutations in PSEN1, PSEN2, and APP | Family history | Acetylcholinesterase inhibitors (Donepezil, Galantamine, and Rivastigmine) | [146,156,157] |

4. Alzheimer’s Disease Diagnosis

AD is a dual clinicopathological condition, which means that two requirements must be met for the definite diagnosis: (1) the presence of a clinical phenotype characterized by symptoms, such as episodic memory impairment or involvement of other cognitive, behavioral, and neuropsychiatric domains and (2) the development of neurological changes, such as the accumulation of NFTs and Aβ plaques in the brain. NFTs and Aβ plaques can be detected only through autopsy; as such, clinical diagnosis relies heavily on the observation of behaviors that are compatible with known clinical features of AD [41,158] and the exclusion of other potential causes [9]. The guidelines of neuropathological assessment of autopsy samples for the definitive diagnosis of AD have been published by the National Institute on Aging and the Alzheimer’s Association in 2012 [159].

In fact, it remains challenging to discriminate AD from other neuropathological dementia despite the advances in research protocols and current diagnostic tools [11]. Currently, AD diagnosis is based on confirming memory loss and cognitive impairments using neurological tests, such as the Montreal Cognitive Assessment (MOCA) [160] and Mini-Mental Status Examination (MMSE) [161]. However, the ultimate AD diagnostic protocol can only be performed post-mortem to detect Aβ and tau NFTs in brains of deceased patients [11]. The current limitations in AD diagnostics burden the development of effective AD treat-
ments since it depends on signs and symptoms, whereas the accurate status of the brain can only be assessed post-death [162]. Currently, scientists are suggesting epigenetic alterations could be exploited as diagnostic surrogates for AD [7,11–16,18,163–171].

5. Epigenetic Changes in Alzheimer’s Disease

Epigenetic modifications have emerged as significant contributors in AD pathology, mediating promises for AD treatment [7,11–16,18,163–171]. Various epigenetic changes, including mitochondrial epigenetics (i.e., mitoepigenetics), DNA methylation and hydroxymethylation, noncoding RNA translation, and histone post-translational modifications have been implicated in AD development [11]. Disruption of both DNA methylation and DNA hydroxymethylation processes has been implicated in many diseases that are classified as neuropathologies, including AD [172]. Interestingly, the key genes involved in AD pathogenesis are regulated by miRNAs and DNA methylation [11,13]. Other studies reported that there is an overlap between distinctively methylated DNA spots in AD and histone signatures in H3K27me3 and H3K4me3 in the Polycomb-repressed (poised) promoter [173]. Further studies declared that indistinguishable 5-methylcytosine (5mC) models are observed in AD patients associated or not associated with schizophrenia [174].

5.1. DNA Methylation

DNA methylation retains fundamental cellular functions and synaptic elasticity in the CNS, and it influences cognitive processes [175]. DNA hydroxymethylation is essential for neurodevelopment and is concentrated in the CNS, which further signifies the importance of DNA methylation [175]. Some studies showed that overall DNA methylation is decreased in AD patients [176–179], while other studies recorded no significant differences in DNA methylation between AD and age-matched healthy individuals [180,181]. DNA methylation patterns that were in connection with AD were investigated for the following genes: glycogen synthase kinase 3 beta (GSK3β) [182,183], ankyrin 1 (ANK1) [184], TREM2 [17], and brain-derived neurotrophic factor (BDNF) [185]. ANK1 methylation has been increased in AD patients [186–189]. An increase in DNA methylation has been also recorded in the dorsolateral prefrontal cortex [187], entorhinal cortex [190], temporal cortex [190], temporal gyrus [191], and the hippocampus. Contrarily, a decrease in DNA methylation has been reported in locus coeruleus, prefrontal cortex [192,193], and blood samples [194]. Additionally, studies showed that 13% of noncoding RNA CpG motifs were methylated in AD patients, leading to a significant increase in 5mC levels in these genetic loci in particular [190].

5.2. Mitochondrial DNA Methylation

Mitochondria generate the energy (ATP) required to vitalize the cell’s reactions, and AD has been postulated to be associated with energetic decrease arising from mitochondrial disorder. Dysfunction of the mitochondrial oxidative phosphorylation and energy-producing cascade increases in reactive oxygen species (ROS) generation and apoptosis such that both are implicated in neurodegeneration and disease development [11–13,16,195–197]. Studies reported that multiple considerable deletions are detected in mitochondrial DNA (mtDNA) and are linked with AD pathogenesis [198]. In addition, mutations of mitochondrial rRNA and tRNAs [199,200], cytochrome C oxidase [200,201], and the regulatory D-loop influence mtDNA copy number, transcription, and translation [202]. Low levels of mtDNA were observed in AD patients having low Aβ and high tau in the cerebrospinal fluid (CSF) and in presymptomatic patients having PSEN1 mutation [203]. Low mtDNA copy number and abnormal propagation of mitochondria were associated with low level of mtDNA in CSF that might act as a biomarker for AD in the preclinical phase [203]. Another study demonstrated a positive correlation between Aβ and CSF mtDNA content but a negative correlation between phosphorylated tau protein and CSF mtDNA levels [204]. Low levels of CSF mtDNA accompanied by low Aβ and high phosphorylated tau assist in distinctive AD diagnosis against other neurological disabilities [204]. Studies revealed an
increase in methylation of mtDNA at CpG and non-CpG repeats of D-loop of AD entorhinal cortex with Braak stages I to II and III to IV [192,205]. However, a significant decrease in mtDNA methylation in AD blood samples was detected [197].

5.3. DNA Hydroxymethylation

Studies revealed that thousands of distinguishable hydroxymethylated regions (DhMRs) in AD brains are associated with an increase of 5hmC levels in intragenic regions [206–208]. Genomic studies reported an increase in 5-hydroxymethylcytosine (5hmC) levels in the F-box and leucine rich motif protein 16 (FBXL16) gene [186]. FBXL16 was reported as a potential AD-associated gene, showing an encoding decrease in microglia cells of mouse AD models [209]. Another study reported a decrease in 5hmC levels in four CPG repeats in ANK1 [186]. Diverse studies confirmed a decrease in 5hmC levels in the AD entorhinal cortex, cerebellum [173], and CA3 region of the hippocampus [210] but an increase in 5hmC levels in AD brains’ parahippocampal gyrus [211], middle frontal gyrus, and middle temporal gyrus [212]. Further studies reported an increase in tau protein deposition and a decrease in astrocytes location [213], whereas one investigation recorded that 5hmC is not localized in AD cerebellum and entorhinal cortex [214]. Another study declared a decrease in 5hmC deposition in AD glial cells of hippocampus CA1 region [210]. Further study investigated the effect of TREM2 on AD pathogenesis and found there is a positive association between 5hmC repeats in exon 2 of TREM2 and TREM2 expression, postulating that an increase in gene expression might assist in tissue repair [215]. TREM2 is encoded in microglia cells and is required in tissue repair, homeostasis, and natural immunity reaction [215].

5.4. Histone Modifications

Histones (H1, H2A, H2B, H3, and H4) are biochemically highly basic proteins rich in arginine and lysine residues. Histones serves as a scaffold, assisting DNA to wrap and condense in eukaryotic nucleus forming nucleosomes [216,217]. Histone modifications are involved in neuronal differentiation and growth, older individuals’ brains homeostasis, and in AD pathology [7,11–14,16,18,164,165,169,171,204,218]. A prevalent lack of heterochromatin was detected in human AD, tau transgenic Drosophila, and mice [219]. Oxidative stress and DNA deterioration were associated with transgenic tau expression and heterochromatin relaxation [219].

Histone modifications, such as abnormal acetylation, were linked with aberrant signaling, apoptosis, inflammation, immunity, and neuroplasticity [220]. Histone acetylation was detected in postmortem AD brains [221–223]. A decrease in histone acetylation was observed in AD temporal lobes [224]. Acetylation of lysine 16 on histone H4 (H4K16ac) is implicated in aging and DNA damage, and such deterioration was previously observed in AD cortex patients [218,225]. However, acetylation of lysine 12 on histone H4 (H4K12ac) was accompanied with memory disturbance [218]. Higher H4K12ac content was detected in MCI but not detected in AD, confirming its role in an infant stage of disease development and aggregation deposition [15]. High levels of acetylated histone as well as H3 and H4 were detected in human post-mortem AD brains [225]. In addition, higher levels of histone deacetylases (HDACs), particularly class I (HDAC2 and HDAC3), were observed in AD brains’ regions that are involved in memory, learning, and neural plasticity. HDACs are linked with cognitive impairments and synaptic functions [171,218]. On the contrary, other investigations declared a decrease in HDACs in dysfunction brains’ regions that are associated with MCI symptoms [11]. In addition, class II HDACs are implicated in AD pathogenesis [226]. An increase in HDAC6 level was discovered in AD brains’ cortex and hippocampus and in AD animal models [226]. HDAC6 influences tau phosphorylation and degradation as well as tubulin acetylation, and it mediates inflammatory processes [169,227]. A decrease in HDAC6 level results in higher clearance and decrease of tau aggregation and consequently assists in nerve survival [220,228], while an increase in HDAC6 level leads to a decrease in α-tubulin acetylation and subsequently disrupts
microtubules’ homeostasis and mitochondrial as well as vesicular transport [220,228]. A decrease in HDAC4 content, another member of class II HDACs, adversely influences learning and memory development [229]. HDAC4 is involved in neural function, and its increase results in apoptosis, whereas its decrease inhibits nerve cell death [229]. Class III HDACs, sirtuins (SIRTs), are involved in synaptic elasticity and memory functions as well as AD pathogenesis [227]. Studies reported that levels of SIRT1 are reduced in the parietal cortex, whereas SIRT1 levels in AD cerebellum are not reduced [171]. Such expression aberrations, probing Aβ and tau deposition, as well as acetylation of lysine 28 of tau protein, lead to tau aggregation [171,220]. Aberrations in histone methylation have been detected in AD patients as well [230]. The levels of histone methyltransferases (HMT) and histone demethylases are significant for brain vitality and memory function [230]. Studies declared that an increase in trimethylation of lysine residue on histone H3 (H3K9), a biomarker of gene silencing and heterochromatin condensation [231], and overexpression of histone lysine methyltransferase 1 (EHMT1) are observed in post-mortem AD brains [232]. The G9a HMT, an enzyme responsible for demethylation of lysine 9 on H3 (H3K9), is involved in cognitive function in mice; however, H3K4 demethylase contributes to human memory deficiency [230]. Studies observed that an increase in phosphorylation of serine 10 on H3 (H3S10), detected in AD hippocampal neurons [233], and an increase in phosphorylation of serine 139 on H2AX, detected in AD astrocytes, might serve as indicators of DNA damage [234]. ADP ribosylation of H1 was detected in AD brains [235]. Altogether, these results shed light on histone aberration in AD pathogenesis and motivate more researchers to explore the complexity of such factor.

5.5. MicroRNA

Diverse microRNAs (miRNAs) target genes are implicated in AD pathogenesis [11–14,16,18,169,171]. There are approximately 161 miRNAs that could contribute to AD pathogenesis, while ten miRNAs have been linked to AD, including miRNA-9, miRNA-29, miRNA-34, miRNA-107, miRNA-125, miRNA-132/-212, miRNA-146, miRNA-155, miRNA-181, and miRNA-206 [190]. Additionally, specific miRNAs were related to myelin sheath formation and others were involved in AD development, such as SIRT1, BACE1, and APP [190]. miRNAs are also involved in APP degradation and Aβ metabolism by modulating the activity of APP-degrading enzymes, such as BACE1 [236]. Furthermore, many miRNAs were found to regulate BACE1 expression, such as miRNA-124, miRNA-135b, miRNA-195, miRNA-15b, miRNA-29c, and miRNA-399-5p [237–240]. Other miRNAs, such as miRNA-219, regulate microtubule-associated protein tau (MAPT) gene (MAPT), while others, such as miRNA-124-3p and miRNA-125b, modulate the activity of kinases that are involved in the phosphorylation of tau protein [183,241–243].

BDNF, or abrineurin, expressed by BDNF, is a potential regulator of synaptic elasticity and transmission that induces miRNA-132 expression [244]. Studies reported that miRNA-132 and miRNA-212 encoding is suppressed in the early AD stage [245,246]. Other studies declared that miRNA-9 modulates neural progenitor cells’ growth, differentiation, and migration [247,248]. In addition, miRNA-9 upregulates ACE1 [249], and subsequently, increases Aβ formation and accumulation [250].

It was found that downregulation of miRNA-9 modulates calcium/calmodulin-dependent protein kinase kinase 2 (CAMKK2) expression [251], resulting in an increase in phosphorylated tau and Aβ deposition through CAMKK2-cyclic adenosine monophosphate-activated protein kinase (AMPK) cascade [183,252]. Modulation of BACE1 encoding is also carried by miRNA-29, implying that an increased level of BACE1 is associated with a decrease in the level of miRNA-29 [253,254]. Studies declared that miRNA-29 regulates neuron navigator 3 (NAV3) that is overexpressed in AD frontal cortices [255]. Studies showed that both miRNA-34 and tau miRNA are upregulated in AD, suggesting a linked mechanism for AD pathogenesis [256]. Studies demonstrated that miRNA-107 expression is suppressed in AD CNS and blood, particularly at the begging of AD. Further studies exhibited negative association between miRNA-107 expression and BACE1, inferring
that BACE1 mRNA could modulate miRNA-107 [257]. In addition, miRNA-107 regulates cyclin-dependent kinase 5 (CDK5) that is responsible for CNS integrity and function [258]. Studies showed that higher levels of miRNA-125 stimulate tau hyperphosphorylation, resulting in promoting mitogen-activated protein kinase/extracellular signal-regulated kinases (MAPK/ERK) signaling and increasing p53 expression [183,241]. Studies revealed that miRNA-132/-212 was linked with cognitive function and was suppressed in AD brains [259]. Studies reported that miRNA-146 expression is modulated by nuclear factor kappa-B (NF-κB), and the overexpression of miRNA-146 paves the way for NF-κB to downregulate the translation of complement factor H (CFH) and subsequently influence the inflammatory reaction in CNS [260].

Studies showed that the overexpression of some microRNAs (miRNA-155, miRNA-146, and miRNA-124) is associated with over production of APP and Aβ [261]. Studies revealed that miRNA-181 was suppressed in AD CNS [262]. Further investigations showed that the downregulation of miRNA-181 is associated with higher level of Aβ expression [262]. Furthermore, the downregulation of miRNA-181 influences MAPK signaling cascade [262]. Other investigations reported that miRNA-206 is overexpressed in AD CSF and blood [51,263].

6. Alzheimer’s Disease Biomarkers

Biomarkers are important tools for the accurate diagnosis of many diseases, including AD. Despite the recent advances in diagnostic methodology for Alzheimer’s disease, differentiation of Alzheimer’s dementia from other forms of dementia remains challenging. The analysis of Aβ-42, total tau protein, and phosphorylated tau (p-tau) from cerebrospinal fluid (CSF) is currently considered the best-established biological marker for the diagnosis of AD as well as differentiation from mild cognitive impairment and other types of dementia. The familiar AD biomarkers are the reduced levels of Aβ in CSF and the appearance of Aβ or tau depositions in the brains of AD patients [264–266]. Additionally, biomarker evidence obtained through PET can be used to attribute the clinical syndrome of dementia or MCI to underlying AD pathology, with varying probability [264]. In most cases, AD diagnosis in living patients continues to rely on the patient’s clinical history, family members with neuropsychological conditions, and the observance of symptom progression over time [41].

Before the early 2000s, the only sure way to know whether a person had AD or another form of dementia was after death through autopsy. Today, we have 12,073 biomarkers linked to AD. An overview of these biomarkers is provided in Figure 3a–d. Approximately 441 biomarkers are either approved or in late-stage clinical studies for AD diagnosis, prognosis, staging, and monitoring of disease progression. The most widely used AD biomarkers are Aβ42 (the major component of amyloid plaques in the brain), tau, and phospho-tau (major components of tau tangles in the brain) [267]. These biomarkers are measured in CSF, which is the clear fluid that surrounds the brain and spinal cord, providing protection and insulation.

In May 2022, the US FDA authorized the use of Lumipulse G beta-Amyloid Ratio (1-42/1-40) in vitro diagnostic test for the assessment of beta-amyloid pathology in CSF samples [268]. The ratio of these two proteins in CSF is indicative of the presence of amyloid plaques. The test is minimally invasive, and it is the first FDA-authorized in vitro diagnostic biomarker for use in individuals being evaluated for AD and other causes of cognitive decline. However, results of the test must be interpreted in conjunction with other patient clinical information. Additionally, Aβ42 levels measured in plasma have been evaluated as a potential biomarker for AD since it is less invasive to sample plasm than CSF. All recommended/approved AD biomarkers for disease diagnosis and prognosis are list in Table 2.
Diagnostics 2022, 12, x FOR PEER REVIEW 13 of 42

Figure 3. An overview of Alzheimer’s disease biomarkers in all stages of clinical development. Biomarkers are presented by (a) type of biomarker, (b) highest phase of biomarker development, (c) clinical phase of development for clinical biomarkers, and (d) according to the biomarker use. Data source: Cortellis Drug Discovery Intelligence, 10 October 2022, https://www.cortellis.com/drugdiscovery/ © 2022 Clarivate. All rights reserved.

Table 2. Highest validity Alzheimer’s disease biomarkers listed according to their biomarker uses in Alzheimer’s disease.

| Biomarker Name                  | Population           | Role                  | Highest Use Validity          | Gene Symbol |
|---------------------------------|----------------------|-----------------------|-------------------------------|-------------|
| 1 Amyloid beta A4 protein       | Mild Cognitive Impairment | Risk Factor          | Recommended/Approved         | APP         |
| 2 Amyloid beta A4 protein       | All                  | Diagnosis             | Recommended/Approved         | APP         |
| 3 Amyloid beta A4 protein       | Early Onset          | Diagnosis             | Recommended/Approved         | APP         |
| 4 Apolipoprotein E              | Mild Cognitive Impairment | Risk Factor          | Recommended/Approved         | APOE        |
| 5 beta-amyloid protein 42       | Mild Cognitive Impairment | Risk Factor          | Recommended/Approved         |             |
| 6 beta-amyloid protein 42       | All                  | Diagnosis             | Recommended/Approved         |             |
| 7 Glucose transporters and hexokinases | Mild Cognitive Impairment | Risk Factor          | Recommended/Approved         |             |
| 8 Glucose transporters and hexokinases | All                  | Diagnosis             | Recommended/Approved         |             |
| 9 Microtubule-associated protein tau | Mild Cognitive Impairment | Risk Factor          | Recommended/Approved         |             |
| 10 Microtubule-associated protein tau | All                  | Diagnosis             | Recommended/Approved         |             |
| 11 Presenilin-1                 | All                  | Diagnosis             | Recommended/Approved         | PSEN1       |
| 12 Presenilin-1                 | Early Onset          | Diagnosis             | Recommended/Approved         | PSEN1       |
| 13 Presenilin-2                 | All                  | Diagnosis             | Recommended/Approved         | PSEN2       |
| 14 Presenilin-2                 | Early Onset          | Diagnosis             | Recommended/Approved         | PSEN2       |

7. Anti-Alzheimer’s Drugs

There are currently 868 anti-Alzheimer’s drugs in different stages of development. However, only 273 drugs are currently under active development by biotech and/or pharma with evidence of active development in the last 6 months, according to Cortellis Drug Discovery Intelligence [269]. The most effective drugs currently approved for AD management are listed in Table 3, and they comprise cholinesterase inhibitors (donepezil,
rivastigmine, and galantamine) and the N-methyl-D-aspartate (NMDA) receptor antagonist (glutamate antagonist) memantine [41,70]. All of these drugs offer symptomatic treatments.

Table 3. Approved symptomatic pharmacological treatments for patients with AD.

| Drug         | Drug Targets | Managed Symptoms                                                                 | Mechanism of Action                                                                 | Disease Stage          |
|--------------|--------------|----------------------------------------------------------------------------------|-----------------------------------------------------------------------------------|-----------------------|
| Donepezil    | AChE         | Improves cognition and behavior                                                   | Cholinesterase inhibitor; inhibition of various aspects of glutamate-induced excitotoxicity; the reduction of early expression of inflammatory cytokines; the induction of a neuroprotective isoform of AChE; the reduction of oxidative stress-induced effects | Mild to moderate AD   |
| Rivastigmine | AChE; BChE   | Improves cognitive functions and daily life activities                            | Cholinesterase inhibitor; increases cholinergic function                           | Mild to moderate AD   |
| Galantamine  | AChE; nicotinic ACh receptor | Improves behavioral symptoms, daily life activities, and cognitive functions | Cholinesterase inhibitor; binds to α-subunit of nicotinic ACh receptors and activates them | Mild to moderate AD   |
| Memantine    | NMDA receptor | Improves learning and memory                                                      | NMDA receptor antagonist (prevents over-activation of glutaminergic system that is involved in neurotoxicity in AD patients) | Moderate to severe AD |

AChE: acetylcholine esterase; AD: Alzheimer’s disease; BChE: butyrylcholinesterase; ACh: acetylcholine; and NMDA: N-methyl-D-aspartate.

7.1. Drugs under Active Development

There are currently 273 drugs under active development for the treatment of AD, including small molecules, biotechnology products, peptides, combinations, and herbal materials (Figure 4a). The majority of these drugs target Aβ42 precursor protein (24.9%), followed by APP (18.7%), MAPT (10.6%), acetylcholinesterase (AChE) (3.3%), cholinergic receptor muscarinic 1 (CHRM1) (3.3%), NMDA receptor (2.2%), tumor necrosis factor (TNF) (2.2%), 5-hydroxytryptamine receptor 6 (5-HTR6), cholinergic receptor muscarinic 4 (CHRM4) (1.8%), glucagon-like peptide 1 receptor (GLP1R), insulin (1.5%), sigma non-opioid intracellular receptor 1 (SIGMAR1) (1.5%), sodium channel (1.5%), and 5-hydroxytryptamine receptor 4 (5-HTRA4) (1.1%). Drug count details are shown in Figure 4b. Additionally, the top organizations developing these drugs as well as the development status of these drugs are shown in Figures 4c and 4d, respectively.

Recently, monoclonal antibodies (mAbs) have revived the hope for AD treatments. Aducanumab, an mAb, targets Aβ aggregates in AD patients’ brains to decrease their formation [10,277]. In 2021, aducanumab was approved for AD and prescribed for individuals with AD-MCI and mild AD dementia [10,277]. It is a humanized recombinant monoclonal antibody to Aβ. In a clinical study on 165 patients, aducanumab demonstrated significant reduction of soluble and insoluble Aβ. Furthermore, aducanumab reduced AD clinical decline measured by Mini-Mental State Examination scores. At 12-month follow-up, cerebral Aβ disappeared from almost 50% of patients diagnosed with mild AD. A Phase III clinical trial on 1638 patients of aducanumab has been terminated due to safety and efficacy issues [278]. In addition, two monoclonal antibodies, donanemab and lecanemab, are currently under US Food and Drug Administration (FDA) investigations [277,279–281].
7.1. Drugs under Active Development

There are currently 273 drugs under active development for the treatment of AD, including small molecules, biotechnology products, peptides, combinations, and herbal materials (Figure 4a). The majority of these drugs target Aβ42 precursor protein (24.9%), followed by APP (18.7%), MAPT (10.6%), acetylcholinesterase (AChE) (3.3%), cholinergic receptor muscarinic 1 (CHRM1) (3.3%), NMDA receptor (2.2%), tumor necrosis factor (TNF) (2.2%), 5-hydroxytryptamine receptor 6 (5-HTR6), cholinergic receptor muscarinic 4 (CHRM4) (1.8%), glucagon-like peptide 1 receptor (GLP1R) (1.5%), sigma non-opioid intracellular receptor 1 (SIGMAR1) (1.5%), sodium channel (1.5%), and 5-hydroxytryptamine receptor 4 (5-HTR4) (1.1%). Drug count details are shown in Figure 4b. Additionally, the top organizations developing these drugs as well as the development status of these drugs are shown in Figure 4c and Figure 4d, respectively.

Figure 4. An overview of Alzheimer’s disease drug discovery pipeline under active development by (a) drug type, (b) top targets, (c) top organizations, and (d) development status. Under active development, according to Cortellis Drug Discovery Intelligence (CDDI) [40] database as of 10 October 2022. Data source: Cortellis Drug Discovery Intelligence, 10 October 2022, https://www.cortellis.com/drugdiscovery/ © 2022 Clarivate. All rights reserved.

The pro-drug of methylene blue, leuco-methylthioninium, is a second-generation tau aggregation inhibitor (TAI) and the only tau-specific agent to undergo Phase III clinical trials. Two Phase III clinical trials were conducted in 2016 to demonstrate the efficacy of different doses of leuco-methylthioninium and to compare the efficacy of monotherapy compared with combination with cholinesterase inhibitors or memantine. A third clinical trial to demonstrate the efficacy of low dose leuco-methylthioninium is still active and recruiting to date [282]. Anti-tau monoclonal antibody (tau vaccine) is an IgG4 antibody that targets aggregated tau protein. Preclinical and Phase I clinical trial data demonstrated that it was safe and might present a potential agent for treating AD. A 96-week Phase II safety and efficacy trial (453 participants with AD) was conducted. Recruitment has completed (in August 2022), but the final study report is not yet published [283]. Gosuranemab is a therapeutic mAb for the N-terminal of extracellular tau. Gosuranemab was demonstrated to be safe and effective in a single ascending dose study. Gosuranemab has been investigated through a Phase II clinical trial (654 participants with MCI or mild AD). However, the study was terminated due to lack of efficacy following the placebo-controlled period readout [284]. Semorinemab is another antibody that targets the extracellular tau. Promising results were concluded from a pilot safety study, and currently, a Phase II clinical trial (272 patients with moderate AD) to investigate cognitive function and functional capacities of patients is still
active [285]. Zagotenemab, an mAb, binds to tau aggregates. Phase I clinical trial (single dose) was conducted on zagotenemab in patients with mild AD [277].

7.2. Withdrawn, Discontinued, or Suspended Drugs

There are 108 drugs that have been either withdrawn, discontinued, or suspended from use for AD. The majority of these drugs were small molecules, but there were some biotechnology products and few peptides (Figure 5a). Many of the drug targets (Figure 5b) are similar to drug targets under active development for AD, which may give the impression that those drug targets may not be successful for the treatment of the disease, especially since many of the big pharmaceutical companies have abandoned them, including Pfizer, Sanofi, Lilly, AstraZeneca, and others (Figure 5c). Table 4 summarizes the major failures and suggests hypotheses explaining them.

Figure 5. An overview of Alzheimer’s disease drugs that were either suspended, withdrawn, or discontinued by (a) drug type, (b) top targets, and (c) top organizations. Under active development, according to Cortellis Drug Discovery Intelligence (CDDI) [40] database as of 10 October 2022. Data source: Cortellis Drug Discovery Intelligence, 10 October 2022, https://www.cortellis.com/drugdiscovery/ © 2022 Clarivate. All rights reserved.
Table 4. Most important drug classes that failed as anti-AD treatments in different stages of clinical trials.

| Drug Category          | Classification | Why Suggested                                                                                                                                                                                                 | Why Failed                                                                                                                                                                                                 |
|------------------------|----------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Monoclonal Antibodies (mABs) | Disease-modifying  | These antibodies target the amyloid protein, and they predominate drug discovery efforts [154]. Amyloid has been considered a promising drug target since it is located outside the nerve cells, and it is toxic to the brain's tissues [154]. | The mABs have not succeeded in eradicating AD because cognitive impairment predisposing dementia does not associate with amyloid precipitation [154]. |
| Gamma (γ-) Secretase Inhibitors | Disease-modifying  | It was proposed that targeting γ-secretase might reduce amyloid production, particularly Aβ42 isoform [160–163]. Phase II trials showed a dose-dependent decrease in both Aβ isoforms (Aβ40 and Aβ42) without significant decrease in tau protein, though the magnetic resonance imaging (MRI) recorded a cerebral atrophy following such treatment [154,165]. Patients showed some improvement at the beginning of treatment. | No distinct response of improvement nor worsening could be traced after 3 months of treatment [154,162]. Side effects were reported with higher doses, such as skin rashes, nausea, and diarrhea, accompanied by higher rate of skin cancer [154,164]. Furthermore, the narrow therapeutic window impeded their proceeding to Phase III [154,165]. |
| Tau Inhibitors         | Disease-modifying  | The tau protein appeared as a potential target for AD dementia since an irregular phosphorylation of tau results in neurofibrillary tangle formation [166–168]. Clinical studies reported that AD progress is related to tangle formation more than that of Aβ [156]. Initially, tau aggregation inhibitors (TAIs) showed better response. | After long-term treatment (approximately 15 months), TAIs failed in AD treatment. Moreover, 15% of patients showed minor improvement without any co-administered therapy [169]. |
| Neurochemical Enhancers | Symptomatic       | Idalopiridine that inhibits 5-hydroxytryptamine 6 (5-HT6) receptors and consequently enhances the release of acetylcholine in the brain, i.e., pro-cholinergic effector [182,183]. Further clinical studies declared that Idalopiridine does not show any promising effect in AD treatment [182,184]. | Side effects of Encenicline were observed in Phase II trials at the maximum dose (2 mg) [185–187]. In addition, the Phase III trials, with doses of 2–3 mg, were terminated due to GI toxicity and eventually discontinued because there was no improvement in cognitive function [185–187]. |
| Miscellaneous          | Symptomatic       | Dimebon is a histamine (H1) antagonist [188]. It affects α-adrenergic and serotoninergic receptors, AMPA and NMDA glutamate receptors, and L-type voltage-gated calcium channels [189]. It exerted a better response in AD patients and one Phase II trial in Russia [189], but it failed in Phase III trials in Austria, Europe, New Zealand, and the US [189]. | |
8. Exploiting Network Biology Approaches in Alzheimer’s Disease Research

Network biology approaches have been suggested as paradigm-changing approaches for the discovery of disease biomarkers, drug targets, and effective drugs for polygenic multifactorial diseases, including cancer, diabetes, psychological disorders, and AD. However, the typical focus on one single type of omics has been a limiting factor for the success of previous systems biology studies because the findings were explaining only a modest portion of the complex disease, and AD was no exception. Therefore, future studies should study multiple omics data simultaneously and apply new technologies, including machine learning (ML) and artificial intelligence (AI) to derive novel multi-system and multi-target hypotheses.

8.1. Previous Alzheimer’s Disease Drug Discovery Failures

Misunderstanding of the disease mechanisms coupled with inconsistent drug development protocols that relied on single-target approaches, in addition to the improper management of drug discovery projects, led to the inopportune nomination of drug targets which contributed to many drug failures [3,286]. Additionally, clinical trial design utilized in drug discovery failed due to many reasons, including the delay in initiation of treatments, incorrect drug doses, or lack of good drug-monitoring biomarkers [287,288]. The success rate in progressing AD clinical trials from one phase to the next has been poor, and the number of therapeutic agents approaching FDA approval is low [289]. Failures in clinical trials might be due to ineffective treatments, drug side effects, or misconducted trials [289]. The improper selection of methodological parameters in clinical trial design [290] impeded the success of previous clinical trials [287–289,291]. In fact, the clinical trials dilemma in psychiatry, neurology, and AD has been discussed elsewhere by many researchers [292–294]. Issues including inaccuracy, incorrectness, and bias hindered clinical trials success [295,296]. Other factors included personal errors, drawbacks in rating scales, and limitations in neuropsychological tests leading to errors regarding the underestimation of the clinical outcome in clinical trials [290,297]. Increasing the number of clinical trials investigating drug effects has been associated with better treatment outcome [289]. Additionally, limitations in cell-based models to probe neurodegenerative diseases, such as AD, contributes to AD failure treatment [298]. The complexity of CNS motivates researchers to integrate the molecular basis of neurodegenerative diseases with the unique organization and construction of brain tissue [298]. This combined approach is displayed via 3D cell models accompanied by microfluidic technology, which are in their early stages and ready for improvement [298]. Subsequently, this integrative system should enrich the preclinical drug development pipeline [298]. The biodiversity of AD-drug design and development needs to unify healthcare workers’ and scientists’ efforts [289]. Other factors that played an important part in the failure of many AD drug development programs were improper diagnostic evaluations, elusive genetic factors, and/or concomitant diseases [299,300].

8.2. Network Biology Approaches Hold the Promise to Revolutionize Alzheimer’s Disease Research

AD is a complex disease associated with multiple perturbations in biological networks and functional network connectivity that are fundamental for normal physiological function; hence, multi-target treatment approaches seem imperative to treat the disease [301–303]. Studies have reported that numerous brain functional networks are significantly impaired in AD patients, including the control network (CON), default mode network (DMN), dorsal attention network (DAN), salience network (SAL), and sensory–motor network (SMN) [304]. In mild AD patients, there is evidence indicating reduced functional network connectivity in the brain is a predisposing factor. Additionally, the DMN is impaired in very mild to mild AD patients, while severe AD patients suffer from disrupted network crosstalk [304]. Thus, network and systems biology approaches that target multiple disease networks and pathways hold great promise to revolutionize AD drug discovery research.
Furthermore, network biology approaches enable the identification of novel disease biomarkers, including quantitative diagnostic and prognostic biomarkers, imaging, and biochemical tests. Novel validated disease biomarkers could potentially equip AD researchers with the proper tools to accurately differentiate between AD and non-AD dementias, which can positively impact drug discovery efforts, clinical trial design, and patient selection for clinical trials [305]. There is agreement among scientists [1–5,22,306] that future AD research should focus on the following: (1) reassessing previous and current prevalent AD pathogenesis hypotheses, (2) identifying effective disease-specific biomarkers, (3) re-evaluating previous disease diagnostic standards, (4) considering new guidelines and procedures for disease control, (5) reorienting drug discovery efforts toward employing approved multi-target approaches and pharmacogenetic hypotheses, (6) updating the managerial requirements for drug design and development, (7) applying pharmacogenomics approaches in biomarker and drug discovery and development, and (8) implementing disease-prevention strategies for susceptible individuals.

8.3. Current Network Biology Efforts

The underlying hypothesis of network medicine has been recruited in the development of multi-target ligands and combination drugs [21]. The multi-target ligands and combination drugs are considered promising network medicines for challenging and complex diseases [307,308]. Clinical studies showed that multi-target ligands and combined drugs are more effective than single-target drugs in complex diseases treatment, including depression, cancer, and infectious diseases, such as the acquired immunodeficiency syndrome (AIDS) [309–312]. Combining donepezil and memantine improve the brain’s cognition function, and patient’s overall status in mild and advanced AD. Additionally, such drugs decrease the rate of clinical decay and are safe and tolerable [307].

The idea of network medicine is based on the hypothesis that diseases occur due to the disruption of biological networks responsible for homeostasis as a result of activation or deactivation of certain proteins or biochemical reactions, which eventually disturb the balance of normal physiology pathways [313–315]. Hence, disease networks are complex disease processes that are caused by irregular diverse genes, proteins, and signaling cascades [308]. Therefore, network medicines intend to restore disrupted disease networks to their default normal physiology status by targeting multiple key effectors in disease pathways [308].

Recent advances in multi-omics data analysis coupled with advancements in computational chemical biology methods led to better disease understanding. As a result, network medicines have been suggested as potential surrogates for identifying effective treatments for complex diseases, including AD [301–303,316]. Additionally, the application of network approaches to AD research projects has shed light on a crosstalk among diverse signaling pathways involved in AD pathogenesis [21]. Further work is required to lay the groundwork for the development of the next-generation anti-AD drugs. Furthermore, the diverse disease networks could not be revived through targeting of a single protein and/or signaling cascade because there are numerous active and spare cellular mechanisms in biological systems [317].

8.4. Multi-Target-Directed Ligands as Network Biology Treatments

The Multi-Target-Directed Ligands (MTDLs) approach is one of the most promising therapeutic interventions for AD patients as well as other complex multifactorial diseases, including cancer, diabetes, and other psychological disorders [318–320]. The design of MTDL hypothesizes that successful disease-modifying treatments of AD should target systems biology pathways rather than selectively targeting individual proteins or drug targets [321,322]. As such, MTDLs can be defined as drugs and/or technologies designed to interact with more than one target involved in the pathogenesis of a defined disease [322–328], surpassing the “one-molecule, one-target” model [313,319]. It has been theorized that potent MTDL should simultaneously target the typical signs of AD,
such as the irregular accumulation of Aβ peptides [329–333], tauopathies [334–337], and the cholinergic insufficiency in CNS [106,338,339]. In addition, the effective MTDL should consider other AD features, such as the oxidative and nitrosative stresses [117,340,341], inflammatory response of brain and spinal cord, excitotoxicity [342], mitochondrial dysfunction [327,343,344], aberrances in calcium [345,346] and other metals [19,267,347], and irregularities in apolipoproteins [348,349].

It is suggested that the rational design of MTDLs can be achieved by two approaches: (1) drug repurposing, considering drug design methods that take into account the biological fingerprints (or biological spectra) of familiar active drugs against other therapeutic receptors where one or more drugs can modulate several targets [269,350–353] and (2) fragment-based drug design, which is based on the core structures of active compounds against specific targets to generate a new merged scaffold with dual or multiple activity against two or more targets [269].

In the first approach, compounds are screened against multiple proteins/drug targets to retrieve hits with the desired biological profiles [350–352]. The main advantage of this approach is that the investigated compounds are often commercially available and clinically proven to be safe, thus reducing development time and costs [269,350,351], and most importantly, the proposed lead might act as a synergistic effector, modulating the disease pathway effectively [354]. However, the optimization protocol of the biological activity of the lead compound to fit the new disease application has been limited [269,350,351]. Therefore, more work is required to improve hit identification and lead optimization. Sometimes the pharmacokinetics properties of the lead hinder the application to new diseases such as AD where drugs have to meet the criteria for CNS drug design [355,356]. The latter, fragment-based, MTDL approach can be designed using three main methods: (1) linking active fragments/compounds using a linker/spacer and keeping known pharmacophoric features [269], (2) fusing or integrating the active compounds to generate a new chemical entity that shares identical features [269], and (3) merging/mixing the selected bioactive compounds to yield a scaffold that has the key functionalities of the pharmacophore [269].

Studies indicated that the major impedance of the MTDL success is the need to maintain or boost the biological activity of the prioritized compounds while preserving drug-like properties [40]. Many MTDLs may have limitations due to lower selectivity towards some drug targets [357–362], while drug development efforts focusing on increasing the biological activity of MTDL may increase the risk of drug toxicity [357–362]. Therefore, MTDLs should be optimized by improving the selectivity towards certain protein targets while reducing drug toxicity [359–362]. Additionally, the designed chimeric entities using the fragment approach have higher molecular weights than the parent compounds, which may affect drug-like properties, while at other times, the merging protocol might be a promising solution for developing oral bioavailable drugs [363–365].

Finally, when considering MTDL, it is crucial to pay special attention to the required physicochemical properties, including pharmacokinetics, pharmacodynamics, hydrophilicity, and hydrophobicity [269]. MTDL design against neurodegenerative disorders should take into account the drug’s blood–brain barrier permeability [355,356].

8.5. Suggested Disease Biomarkers and Disease Modifying Drugs

Known diagnostic and prognostic biomarkers for AD [269] significantly enrich pathways involved in inflammation and immune regulation. AD biomarkers can be divided into two groups: 168 EOAD biomarkers [154,366] and 932 LOAD biomarkers [367,368]. There are 69 biomarkers that overlap between EOAD and LOAD: ACO2, ACTB, ACTG1, ADAM10, ADIPOQ, ADRA1A, AIF1, APP, ANG, ACE, APOE, ABCA7, ATP6V1B2, ATP2A2, AURKC, AXL, BACE1, CACNA1G, CD33, CLP1, CLU, CR1, Dicer1, DUSP13, DNMBP, FNDCS5, GRK5, GBA1, GRN, H3C1, H3C10, H3C11, H3C12, H3C2, H3C3, H3C4, H3C6, H3C7, H3C8, IL1B, IL6, IL6r, KIF5A, HLA-DRA, MTHFR, MAPT, MBP, NSE, NDRG4, NRGN, NCSN, NSUN2, PAK1, PLD3, PSEN1, RTN3, SLC10A3, SLC12A5, SLC24A4, SORBS2, SORL1, SPARCL1, TCIRG1, TYROBP, TREM2, TNF, YWHAG, VSNL1, and VWA2.
In order to get a better idea of these 69 overlapping biomarkers, we used the compared experiment workflow in MetaCore [39] to compare enrichments results in pathway maps for EOAD and LOAD biomarkers. We found that the top enriched pathway map by common disease biomarkers for EOAD and LOAD is “protein-folding and maturation related to angiotensin system maturation” (Figure 6).

**Figure 6.** Top enriched pathway map for ‘common’ biomarkers of EOAD and LOAD. The pathway map representing protein-folding and maturation for the angiotensin system maturation. Connections between network objects on the map are referred to as links (or edges). A link identifies an interaction or a logical relation between two nodes. The type of interaction or relation is reflected by an appropriate symbol placed in the middle of the link. B = binding (i.e., physical interaction between molecules); C = cleavage of a protein at a specific site, yielding distinctive peptide fragments and carried out by enzymes or compounds; red arrows = inhibition; green arrows = activation; grey arrows = unspecified action; solid purple arrows = emergence in disease; light violet text box = normal process; pink text box = pathological processes; white text box with blue outline = notes; grey block = reaction; blue block = normal process; pink block = pathological process; starred network objects = groups or complex processes; red thermometers on pathway map = network object is a validated biomarker for AD, according to the Cortellis Drug Discovery Intelligence (CDDI) database [40]; thermometer 1 for EOAD, and thermometer 2 for LOAD; a pink hexagon with a capital D on the upper left side of the network object indicates an AD biomarker according to MetaCore™; a green hexagon on the upper left side of the network object with a capital T indicates that the network object is expressed in the brain. Map generated using MetaCore™ version 21.4. MetaCore™, a Cortellis™ solution, 14 October 2022, © 2022 Clarivate. All rights reserved.
LOAD biomarkers led to more significant enrichments of immune system and allergic response pathways, apoptosis, tissue remodeling and repair, cell differentiation, cell cycle regulation, and neurofibromatosis [366], while EOAD led to more significant enrichments of heart failure pathway maps, stem cells, spermatogenesis, lipid biosynthesis regulation, and blood clotting pathways [366].

9. Artificial Intelligence and Machine Learning Approaches

Machine learning (ML) and artificial intelligence (AI) have been used successfully to extract insight from ‘big’ biological data [369–371]. Domain expertise from biology, genetics, elderly medicine, psychiatry, psychology, neurology, and neuroscience could be combined with new bioinformatics and statistical analytical tools to gain insight from multi-omics data. Such insight is valuable for providing answers for challenging research questions, and it can be achieved through the use of theoretical modeling [372,373]. In AD research, ML and AI can answer critical questions about combination diagnostic biomarkers, AD patient subgroups, and disease pathogenesis, thus supporting the identification of a personalized treatments for AD patients [374,375]. In fact, the use of AI has been suggested to probe the pathogenesis mechanisms of AD by analyzing big multi-omics data in parallel [376,377]. Additionally, AI has the capability to differentiate AD patients from other patients suffering from non-AD cognition impairment. It can also anticipate the progression from MCI to AD dementia and assign a tailored treatment for each individual patient [376]. Furthermore, the application of ML and AI approaches to AD research data, can lead to novel hypotheses regarding efficient interventions for AD patients [376]. AI can also aid in the diagnosis of the early stage of dementia [268].

Many research efforts focused on utilizing ML and AI approaches to mine data from clinicaltrials.gov records to evaluate anti-AD therapeutics in different stages of clinical development to study their mechanisms of action and important clinical trial characteristics [10,372,378–382]. AI and ML approaches can lead to important discoveries by learning from the recent advances in clinical trials and anti-Alzheimer’s drug development pipelines [383–388]. Complex AI-based models could be exploited to inform researchers and health care providers about diverse disease etiologies, effective diagnostic biomarkers [375], and individualized treatments based on network biology approaches [389,390].

10. Exploring Epigenetic Treatments

Studies showed that DNA methylation/hydroxymethylation is dysregulated in AD patients prior the onset of clinical symptoms [11]. These were presented in a prospective study on autopsied brains, as level of methylation, in terms of 5mC levels, in presymptomatic patients is similar to those with AD patients [189]. The levels of 5mC, 5hmC, and ten–eleven translocation 1 (TET1) proteins were elevated in preclinical AD patients and AD patients compared with the control group [171,211]. Although further validation is required, DNA methylation/hydroxymethylation may be used as a biomarker for AD diagnosis [11].

Histone modifications, particularly acetylation, deacetylation, and methylation dysregulation, play a role AD pathogenesis [11]. HDACs are highly expressed in patients with AD [171,218], affecting learning, memory, and cognition; hence, HDAC inhibitors (HDACi) are considered a potential treatment option [391]. Studies on AD patients showing low histone acetylation were reported [211,224,225], allowing the potential use of histone acetyltransferases (HATs) [211]. Increased levels of histone methylation and histone methyltransferase enzyme mRNA were reported in postmortem brains of AD patients [11,218]. Although the loss of histone methyltransferase function would affect learning capabilities in AD patients [11], the use of partial histone methyltransferase inhibitors [211] would restore the balance between histone methylation and demethylation in patients with AD to maintain brain integrity and memory [230]. Inhibitor of histone acetyltransferases (INHAT) is reported to bind to histones and block their access to HATs [392]. Studies showed that ANP32A, which is a component of INHAT and inhibitor of protein phosphatase-2A, is
upregulated in AD patients [393,394]. In an in vivo study, the down regulation of ANP32A would reduce INHAT formation and allow for histone acetylation [395]. Collectively, drugs from those classes would comprise potential therapeutic options for AD treatment.

HDACi are considered to be non-selective [220], but they are beneficial, as they reduce AD hallmarks [225]. The use of HDACi that selectively inhibits HDAC2 and HDAC3 would improve cognition, in contrast to inhibiting HDAC1 that would result in neurotoxicity [11,225]. HDAC6 selective inhibitors were also shown to have neuroprotective effects [228,229]. Sirtuins, which are a class of HDACs, contribute to AD pathogenesis and selective inhibitors would also be beneficial [227,229]. Although some HATs showed better response than non-selective HDACi, their low membrane permeability and solubility limit their use in AD treatment [11].

The miRNAs are responsible for the regulation of gene expression through post-transcriptional gene silencing [396]. In relation to AD, several studies summarized by Nikolac Perkovic et al., 2021 [11] showed that miRNAs would be either downregulated or upregulated, altering proteins and enzymes expression responsible for AD pathology. Hence, the use of miRNA mimics to downregulate the expression of genes or proteins [397] or anti-miRNA therapies to alter the function of a specific miRNA [398] are also considered potential treatment options for AD patients.

11. Genetic Treatments

Targeting genetic alterations in AD patients and consequent gene editing and correction is another potential treatment strategy. These include the use of programmable nucleases, such as zinc finger proteins (ZFP), transcription activator-like effectors (TALE), and RNA-guided clustered regularly interspaced short palindromic repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) [399]. The latter showed more promising results for AD treatment and other neurological diseases than did ZFP and TALE [400–402]. The presence of the mutant Cas9 protein, dead Cas9 (dCas9), advanced the CRISPR/Cas9 editing tool, resulting in the emergence of CRISPR interference (CRISPRi) and CRISPR activation (CRISPRa) technologies, in which dCas9 is fused or interacts with transcriptional repressors or activators, respectively [403]. With regard to epigenetics, AD, and dCas9 protein, studies showed promising results with targeting histone demethylase [404], histone acetyltransferase [405], and histone methyltransferases [406,407].

12. Non-Pharmacological Treatment Options and Preventive Measures

Non-pharmacological treatments encompass several recommendations for various lifestyle modifications, including physical and social activity, tobacco cessation, alcohol consumption, weight management, nutrition, and regular exercise. Other interventions include underlying-disease management (e.g., hypertension, diabetes, dyslipidemia, depression, and hearing loss), as stated in WHO guidelines [408]. More studies should assess the relationship between vaccines and AD; it was found that flu vaccines reduce the risk of AD development [409]. However, the protective mechanisms have not yet been elucidated.

Aberrations in the ecosystem of microbiome have been implicated in diverse gastrointestinal and metabolic dysfunction, such as diabetes, insulin resistance, obesity, and inflammatory bowel disease [410]. In addition, studies showed that changes in gut microbiome is associated with neurological disorders, such as multiple sclerosis (MS), autism, and Parkinson’s disease [411–413]. Studies recorded a decrease in microbial diversity in gut microbiome of AD patients [414–421]. Further studies in rats suggested that alterations in gut microbiome might proceed Aβ deposition [422].

13. Special Considerations for Clinical Trials

Aspects to be considered when designing a clinical trial include trial rationale, outcomes of interest, statistical analysis design, sample size and recruitment, and interim monitoring [423]. Common clinical trial designs include single-arm trials, placebo-controlled trials, crossover trials, and factorial trials [424]. In AD-related clinical trials, infrastructure
and technology, cultures and linguistics, regulatory and reimbursement issues, academia and industry harmonization, availability, and access were considered to be the ultimate challenges that limit the conducting of successful clinical trials [425].

According to NLM’s ClinicalTrials.gov Beta (beta.clinicaltrials.gov), 109 clinical trials related to AD were terminated in the last ten years [19]. AD clinical trials were terminated due to the following reasons: unavailability of further funding, halted visits due to COVID-19, feasibility of enrolment, safety issues, slow recruitment of eligible participants (patients), inappropriate study design to achieve the trial’s endpoint, new safety or efficacy data from other studies, unfavourable risk–benefit ratio, and inappropriate dosage settings. Yet, patient recruitment remains the ultimate determinant in AD clinical trials.

Therefore, there is a need for new and advanced clinical trials designs to accelerate passage through the legal authorities’ requirements to register new promising molecules for treatment and/or prevention of AD. However, new investigation approaches need to be fully validated before they can be implemented in clinical trials [426].

14. Conclusions

AD is a multifactorial and polygenetic disease. Novel disease diagnostic biomarkers and disease-modifying treatments are required to halt or slow the onset and disease progression, decrease behavioral aberrations, and ameliorate cognition in AD patients. The recent advances in network biology approaches coupled with the advances in clinical trial design and protocols, in additional to the availability of powerful machine learning and artificial intelligence algorithms, hold promise to identify novel diagnostic biomarkers, better drug targets, and effective disease-modifying drugs. Herein, we provide a comprehensive review on Alzheimer’s disease highlighting the mainstream hypotheses explaining disease pathophysiology as well as current disease treatments and drug discovery projects. We also emphasize the recent scientific evidence implicating epigenetic mechanisms and the microbiome in AD pathogenesis and progression. We suggest that the application of AI and ML approaches in analyzing AD network biology derived from AD data, including genetic, transcriptomic, epigenetic, and metagenomic data would revolutionize our understanding of the disease pathways and will lead to the discovery of novel biomarkers and drug targets. Ultimately, these studies will increase our chances of identifying validated diagnostic biomarkers and effective disease-modifying cures. Hence, breakthrough discoveries in AD research are more likely to occur in the near future. This review provides a summary of the current hypotheses regarding AD pathogenesis in addition to the most recent advances in the search of effective disease biomarkers and drug targets. This review also details AD drugs in various stages of development and highlights technologies that are expected to accelerate AD drug and biomarker discoveries.

Author Contributions: Conceptualization, R.H.; software, R.H.; formal analysis, R.H.; investigation, R.H., D.A.S., O.H.A. and A.Q.A.B.; resources, R.H., D.A.S., O.H.A. and A.Q.A.B.; biomarker data curation, R.H.; writing—original draft preparation, R.H., D.A.S., O.H.A. and A.Q.A.B.; writing—review and editing, R.H., D.A.S., O.H.A. and A.Q.A.B.; visualization, R.H.; supervision, R.H.; project administration, R.H.; funding acquisition, R.H. and D.A.S. All authors have read and agreed to the published version of the manuscript.

Funding: R.H. and D.A.S. acknowledge support from the Deanship of Scientific Research at Al-Zaytoonah University of Jordan (Grant number 2020-2019/17/03).

Informed Consent Statement: Not applicable.

Data Availability Statement: Data supporting the reported results can be requested by contacting the corresponding author directly.

Acknowledgments: The authors acknowledge funding from the Deanship of Scientific Research at Al-Zaytoonah University of Jordan (Grant number 2020-2019/17/03).

Conflicts of Interest: The authors declare no conflict of interest.
References

1. Cacabelos, R. Pharmacogenomics of Alzheimer’s and Parkinson’s diseases. *Neurosci. Lett.* 2020, 726, 133807. [CrossRef] [PubMed]

2. Cacabelos, R.; Meyyazhagan, A.; Carril, J.C.; Cacabelos, P.; Teijido, O. Pharmacogenetics of vascular risk factors in Alzheimer’s disease. *J. Pers. Med.* 2018, 8, 3. [CrossRef] [PubMed]

3. Cacabelos, R. Have there been improvements in Alzheimer’s disease drug discovery over the past 5 years? *Expert Opin. Drug Discov.* 2018, 13, 523–538. [CrossRef] [PubMed]

4. Cacabelos, R. Pharmacogenomics and therapeutic prospects in Alzheimer’s disease. *Expert Opin. Pharmacother.* 2005, 6, 1967–1987. [CrossRef] [PubMed]

5. Cacabelos, R.; Cacabelos, P.; Torrellas, C.; Tellado, I.; Carril, J.C. Pharmacogenomics of Alzheimer’s disease: Novel therapeutic strategies for drug development. *Methods Mol. Biol.* 2014, 1175, 323–556. [CrossRef] [PubMed]

6. 2022 Alzheimer’s disease facts and figures. *Alzheimers Dement.* 2022, 18, 700–789. [CrossRef]

7. Mastroeni, D.; Grover, A.; Delvaux, E.; Whiteside, C.; Coleman, P.D.; Rogers, J. Epigenetic mechanisms in Alzheimer’s disease. *Neurobiol. Aging* 2011, 32, 1161–1180. [CrossRef]

8. Alzheimer’s Association. 2021 Alzheimer’s disease facts and figures. *Alzheimers Dement.* 2021, 17, 327–406. [CrossRef]

9. Scheltens, P.; De Strooper, B.; Kivipelto, M.; Holstege, H.; Chételat, G.; Teunissen, C.E.; Cummings, J.; van der Flier, W.M. Alzheimer’s disease. *Lancet* 2021, 397, 1577–1590. [CrossRef]

10. Cummings, J.; Lee, G.; Nahed, P.; Kambar, M.E.Z.N.; Zhong, K.; Fonseca, J.; Taghva, K. Alzheimer’s disease drug development pipeline: 2022. *Alzheimer Dement. Transl. Res. Clin. Interv.* 2022, 8, e12295. [CrossRef]

11. Nikolic Perkovic, M.; Videtic Paska, A.; Konjevod, M.; Kouter, K.; Svob Strac, D.; Nedic Erjavec, G.; Pivac, N. Epigenetics of Alzheimer’s Disease. *Biomolecules* 2021, 11, 195. [CrossRef]

12. Millan, M.J. The epigenetic dimension of Alzheimer’s disease: Causal, consequence, or curiosity? *Dialogues Clin. Neurosci.* 2022, 16, 373–393. [CrossRef] [PubMed]

13. Adwan, L.; Zawia, N.H. Epigenetics: A novel therapeutic approach for the treatment of Alzheimer’s disease. *Pharmacol. Ther.* 2013, 139, 41–50. [CrossRef] [PubMed]

14. Tecalco-Cruz, A.C.; Ramirez-Jarquin, J.O.; Alvarezsanchez, M.E.; Zepeda-Cervantes, J. Epigenetic basis of Alzheimer disease. *World J. Biol. Chem.* 2020, 11, 62. [CrossRef]

15. Stoccoro, A.; Coppedè, F. Role of epigenetics in Alzheimer’s disease pathogenesis. *Neurodegener. Dis. Manag.* 2018, 8, 181–193. [CrossRef] [PubMed]

16. Alagiaikrishnan, K.; Gill, S.S.; Fagarasanu, A. Genetics and epigenetics of Alzheimer’s disease. *Postgrad. Med. J.* 2012, 88, 522–529. [CrossRef] [PubMed]

17. Ozaki, Y.; Yoshino, Y.; Yamazaki, K.; Sao, T.; Mori, Y.; Ochi, S.; Yoshida, T.; Mori, T.; Iga, J.I.; Ueno, S. DNA methylation changes at TREM2 intron 1 and TREM2 mRNA expression in patients with Alzheimer’s disease. *J. Psychiatr. Res.* 2017, 92, 74–80. [CrossRef]

18. Sharma, V.K.; Mehta, V.; Singh, T.G. Alzheimer’s Disorder: Epigenetic Connection and Associated Risk Factors. *Curr. Neuropharmacol.* 2020, 18, 740–753. [CrossRef]

19. Adlard, P.A.; Bush, A.I. Metals and Alzheimer’s Disease: How Far Have We Come in the Clinic? *J. Alzheimers Dis.* 2018, 62, 1369–1379. [CrossRef]

20. Anand, R.; Gill, K.D.; Mahdi, A.A. Therapeutics of Alzheimer’s disease: Past, present and future. *Neuropsycharmacology* 2014, 76, 27–50. [CrossRef]

21. Zheng, H.; Fridkin, M.; Youdim, M. New approaches to treating Alzheimer’s disease. *Perspect. Medicin. Chem.* 2015, 7, PMC-S13210. [CrossRef]

22. Cacabelos, R.; Teijido, O. Epigenetic drug discovery for Alzheimer’s disease. In *Epigenetics of Aging and Longevity*; Moskalev, A.M., Eds.; Elsevier: Amsterdam, The Netherlands, 2018; Volume 4, pp. 453–495.

23. Oliver, D.M.; Reddy, P.H. Small molecules as therapeutic drugs for Alzheimer’s disease. *Mol. Cell. Neurosci.* 2019, 96, 47–62. [CrossRef] [PubMed]

24. Parums, D.V. Targets for Disease-Modifying Therapies in Alzheimer’s Disease, Including Amyloid β and Tau Protein. *Med. Sci. Monit.* 2021, 27, e934071–e934077.

25. Haass, C. Take five–BACE and the γ-secretase quartet conduct Alzheimer’s amyloid beta-peptide generation. *EMBO J.* 2004, 23, 483–488. [CrossRef] [PubMed]

26. Eratne, D.; Loi, S.M.; Farrand, S.; Kelso, W.; Velakoulis, D.; Looi, J.C. Alzheimer’s disease: Clinical update on epidemiology, pathophysiology and diagnosis. *Australas. Psychiatry* 2018, 26, 347–357. [CrossRef]

27. Naseri, N.N.; Wang, H.; Guo, J.; Sharma, M.; Luo, W. The complexity of tau in Alzheimer’s disease. *Neurosci. Lett.* 2019, 705, 183–194. [CrossRef]

28. Grundke-Iqbal, I.; Iqbal, K.; George, L.; Tung, Y.C.; Kim, K.S.; Wisniewski, H.M. Amyloid protein and neurofibrillary tangles coexist in the same neuron in Alzheimer disease. *Proc. Natl. Acad. Sci. USA* 1989, 86, 2853–2857. [CrossRef]

29. Greenberg, S.G.; Davies, P. A preparation of Alzheimer paired helical filaments that displays distinct tau proteins by polyacrylamide gel electrophoresis. *Proc. Natl. Acad. Sci. USA* 1990, 87, 5827–5831. [CrossRef]

30. Lee, V.M.; Balin, B.J.; Otvos, L., Jr.; Trojanowski, J.Q. A68: A major subunit of paired helical filaments and derivatized forms of normal Tau. *Science* 1991, 251, 675–678. [CrossRef]
31. Kondo, J.; Honda, T.; Mori, H.; Hamada, Y.; Miura, R.; Ogawara, M.; Ihara, Y. The carboxyl third of tau is tightly bound to paired helical filaments. Neuron 1988, 1, 827–834. [CrossRef]
32. Nukina, N.; Ihara, Y. One of the antigenic determinants of paired helical filaments is related to tau protein. J. Biochem. 1986, 99, 1541–1544. [CrossRef]
33. Wood, J.G.; Mirra, S.S.; Pollock, N.J.; Binder, L.I. Neurofibrillary tangles of Alzheimer disease share antigenic determinants with the axonal microtubule-associated protein tau (tau). Proc. Natl. Acad. Sci. USA 1986, 83, 4040–4043. [CrossRef] [PubMed]
34. Goedert, M.; Wischik, C.M.; Crowther, R.A.; Walker, J.E.; Klug, A. Cloning and sequencing of the cDNA encoding a core protein of the paired helical filament of Alzheimer disease: Identification as the microtubule-associated protein tau. Proc. Natl. Acad. Sci. USA 1988, 85, 4051–4055. [CrossRef] [PubMed]
35. Grundke-Iqbal, I.; Iqbal, K.; Quinlan, M.; Tung, Y.C.; Zaidi, M.S.; Wisniewski, H.M. Microtubule-associated protein tau. A component of Alzheimer paired helical filaments. J. Biol. Chem. 1986, 261, 6084–6089. [CrossRef] [PubMed]
36. Ihara, Y.; Nukina, N.; Miura, R.; Ogawara, M. Phosphorylated tau protein is integrated into paired helical filaments in Alzheimer’s disease. J. Biochem. 1986, 99, 1807–1810. [CrossRef] [PubMed]
37. Goedert, M.; Spillantini, M.G.; Cairns, N.J.; Crowther, R.A. Tau proteins of Alzheimer paired helical filaments: Abnormal phosphorylation of all six brain isofoms. Neuron 1992, 8, 159–168. [CrossRef]
38. Greenberg, S.G.; Davies, P.; Schein, J.D.; Binder, L.I. Hydrofluoric acid-treated tau PHF proteins display the same biochemical properties as normal tau. J. Biol. Chem. 1992, 267, 564–569. [CrossRef]
39. MetaCoreTM Version 20.3 Build. Available online: https://portal.genego.com/ (accessed on 10 October 2022).
40. Cortellis Drug Discovery Intelligence. Available online: https://www.cortellis.com/drugdiscovery/home (accessed on 10 October 2022).
41. Scheltens, P.; Blennow, K.; Breteler, M.M.; de Strooper, B.; Frisoni, G.B.; Salloway, S.; Van der Flier, W.M. Alzheimer’s disease. Lancet 2012, 379, 1986–1993. [CrossRef] [PubMed]
42. Chartier-Harlin, M.C.; Crawford, F.; Houlden, H.; Warren, A.; Hughes, D.; Fidani, L.; Goate, A.; Rossor, M.; Roques, P.; Hardy, J.; et al. Early-onset Alzheimer’s disease caused by mutations at codon 717 of the beta-amyloid precursor protein gene. Nature 1992, 359, 325–327. [CrossRef] [PubMed]
43. Haass, C.; Koo, E.H.; Mellon, A.; Hung, A.Y.; Selkoe, D.J. Targeting of cell-surface beta-amyloid precursor protein to lysosomes: Alternative processing into amyloid-bearing fragments. Nature 1992, 357, 500–503. [CrossRef]
44. Haass, C.; Schlossmacher, M.G.; Hung, A.Y.; Vigo-Pelfrey, C.; Mellon, A.; Ostanzevski, B.L.; Lieberburg, I.; Koo, E.H.; Schenk, D.; Teplow, D.B.; et al. Amyloid beta-peptide is produced by cultured cells during normal metabolism. Nature 1992, 359, 322–325. [CrossRef] [PubMed]
45. Haass, C.; Selkoe, D.J. Cellular processing of beta-amyloid precursor protein and the genesis of amyloid beta-peptide. Cell 1993, 75, 1039–1042. [CrossRef] [PubMed]
46. Seubert, P.; Vigo-Pelfrey, C.; Esch, F.; Lee, M.; Dovey, H.; Davis, D.; Sinha, S.; Schlossmacher, M.; Whaley, J.; Swindlehurst, C.; et al. Production of the Alzheimer amyloid beta protein by normal proteolytic processing. Science 1992, 258, 126–129. [CrossRef] [PubMed]
47. Busciglio, J.; Gabuzda, D.H.; Matsudaia, P.; Yankner, B.A. Generation of beta-amyloid in the secretory pathway in neuronal and nonneuronal cells. Proc. Natl. Acad. Sci. USA 1993, 90, 2092–2096. [CrossRef] [PubMed]
48. Haass, C.; Hung, A.Y.; Schlossmacher, M.G.; Eltersdorf, T.; Teplow, D.B.; Selkoe, D.J. Normal cellular processing of the beta-amyloid precursor protein results in the secretion of the amyloid beta peptide and related molecules. Ann. N. Y. Acad. Sci. 1993, 695, 109–116. [CrossRef] [PubMed]
49. Haass, C.; Kaether, C.; Thimakaran, G.; Sisodia, S. Trafficking and proteolytic processing of APP. Cold Spring Harb. Perspect. Med. 2012, 2, a006270. [CrossRef] [PubMed]
50. Tian, N.; Cao, Z.; Zhang, Y. MiR-206 decreases brain-derived neurotrophic factor levels in a transgenic mouse model of Alzheimer’s disease. Neurosci. Bull. 2014, 30, 191–197. [CrossRef] [PubMed]
51. Chartier-Harlin, M.C.; Crawford, F.; Houlden, H.; Warren, A.; Hughes, D.; Fidani, L.; Goate, A.; Rossor, M.; Roques, P.; Hardy, J.; et al. Early-onset Alzheimer’s disease caused by mutations at codon 717 of the beta-amyloid precursor protein gene. Nature 1991, 353, 844–846. [CrossRef] [PubMed]
52. Haass, C.; Selkoe, D.J. Alzheimer’s disease: Genes, proteins, and therapy. Physiol. Rev. 2001, 81, 741–766. [CrossRef]
53. Schenk, D.; Basi, G.S.; Pargalos, M.N. Treatment strategies targeting amyloid beta-protein. Cold Spring Harb. Perspect. Med. 2012, 2, a006387. [CrossRef] [PubMed]
54. Mullan, M.; Crawford, F.; Axelman, K.; Houlden, H.; Lilius, L.; Winblad, B.; Lannfelt, L. A pathogenic mutation for probable Alzheimer’s disease in the APP gene at the N-terminus of beta-amyloid. Nat. Genet. 1992, 1, 345–347. [CrossRef] [PubMed]
55. Suzuki, N.; Cheung, T.T.; Cai, X.D.; Odaka, A.; Otvos, L.; Jr.; Eckman, C.; Golde, T.E.; Younkin, S.G. An increased percentage of long amyloid beta protein secreted by familial amyloid beta protein precursor (beta APP717) mutants. Science 1994, 264, 1336–1340. [CrossRef]
57. Nilsberth, C.; Westling-Danielsson, A.; Eckman, C.B.; Condron, M.M.; Axelman, K.; Forsell, C.; Stenh, C.; Luthman, J.; Teplow, D.B.; Younkin, S.G.; et al. The ‘Arctic’ APP mutation (E693G) causes Alzheimer’s disease by enhanced Abeta protofibril formation. *Nat. Neurosci.* 2001, 4, 887–893. [CrossRef] [PubMed]

58. Levy, E.; Carman, M.D.; Fernandez-Madrid, I.J.; Power, M.D.; Lieberburg, I.; van Duinen, S.G.; Bots, G.T.; Luyendijk, W.; Frangione, B. Mutation of the Alzheimer’s disease amyloid gene in hereditary cerebral hemorrhage, Dutch type. *Science* 1990, 248, 1124–1126. [CrossRef]

59. Citron, M.; Oltersdorf, T.; Haass, C.; McConlogue, L.; Hung, A.Y.; Seubert, P.; Vigo-Pelfrey, C.; Lieberburg, I.; Selkoe, D.J. Mutation of the beta-amyloid precursor protein in familial Alzheimer’s disease increases beta-protein production. *Nature* 1992, 360, 672–674. [CrossRef] [PubMed]

60. Cai, X.D.; Golde, T.E.; Younkin, S.G. Release of excess amyloid beta protein from a mutant amyloid beta protein precursor. *Science* 1993, 259, 514–516. [CrossRef]

61. Jarrett, J.T.; Berger, E.P.; Lansbury, P.T., Jr. The C-terminus of the beta protein is critical in amyloidogenesis. *Ann. N. Y. Acad. Sci.* 1993, 695, 144–148. [CrossRef]

62. Tian, Y.; Bassit, B.; Chau, D.; Li, Y.M. An APP inhibitory domain containing the Flemish mutation residue modulates γ-secretase activity for Aβ production. *Nat. Struct. Mol. Biol.* 2010, 17, 151–158. [CrossRef] [PubMed]

63. Li, Y.M.; Xu, M.; Lai, M.T.; Huang, Q.; Castro, J.L.; DiMuzio-Mower, J.; Harrison, T.; Lelliis, C.; Nadin, A.; Nedevuil, J.G.; et al. Photoactivated γ-secretase inhibitors directed to the active site covalently label presenilin 1. *Nature* 2000, 405, 689–694. [CrossRef]

64. Wolfe, M.S.; Xia, W.; Ostaszewski, B.L.; Diehl, T.S.; Kimberly, W.T.; Selkoe, D.J. Two transmembrane aspartates in presenilin-1 required for presenilin endoproteolysis and γ-secretase activity. *Nature* 1999, 398, 513–517. [CrossRef] [PubMed]

65. Esler, W.P.; Kimberly, W.T.; Ostaszewski, B.L.; Diehl, T.S.; Moore, C.L.; Tsai, J.Y.; Rahmatt, T.; Xia, W.; Selkoe, D.J.; Wolfe, M.S. Transition-state analogue inhibitors of γ-secretase bind directly to presenilin-1. *Nat. Cell Biol.* 2000, 2, 428–434. [CrossRef] [PubMed]

66. De Strooper, B.; Saftig, P.; Craessaerts, K.; Vanderstichele, H.; Guhde, G.; Annaert, W.; Von Figura, K.; Van Leuven, F. Deficiency of presenilin-1 inhibits the normal cleavage of amyloid precursor protein. *Nature* 1998, 391, 387–390. [CrossRef] [PubMed]

67. Karch, C.M.; Goate, A.M. Alzheimer’s disease risk genes and mechanisms of disease pathogenesis. *Biol. Psychiatry* 2015, 77, 43–51. [CrossRef]

68. Szaruga, M.; Munteanu, B.; Lismont, S.; Veugelen, S.; Horr; Jarrett, J.T.; Berger, E.P.; Lansbury, P.T., Jr. The C-terminus of the beta protein is critical in amyloidogenesis. *EMBO J.* 2001, 20, 5301–5305. [CrossRef] [PubMed]

69. Williams, D.R. Tauopathies: Classification and clinical update on neurodegenerative diseases associated with microtubule-associated protein tau. *Intern. Med. J.* 2006, 36, 652–660. [CrossRef] [PubMed]

70. Ambadipudi, S.; Biernat, J.; Riedel, D.; Mandelkow, E.; Zweckstetter, M. Liquid-liquid phase separation of the microtubule-binding helical filament-tau. *Lancet Neurol.* 2013, 12, 609–622. [CrossRef] [PubMed]

71. Chang, Z.; Obianyo, O.; Dall, E.; Du, Y.; Fu, H.; Liu, X.; Kang, S.S.; Song, M.; Yu, S.P.; Cabrele, C.; et al. Inhibition of delta-secretase improves cognitive functions in mouse models of Alzheimer’s disease. *Nature Comm.* 2017, 8, 14740. [CrossRef]
84. Wang, Z.H.; Liu, P.; Liu, X.; Manfredsson, F.P.; Sandovai, I.M.; Yu, S.P.; Wang, J.Z.; Ye, K. Delta-Secretase Phosphorylation by SRPK2 Enhances Its Enzymatic Activity, Provoking Pathogenesis in Alzheimer’s Disease. Mol. Cell 2017, 67, 812–825.e5. [CrossRef] [PubMed]
85. Zhang, Z.; Song, M.; Liu, X.; Kang, S.S.; Kwon, I.S.; Duong, D.M.; Seyfried, N.T.; Hu, W.T.; Liu, Z.; Wang, J.Z.; et al. Cleavage of tau by asparagin endopeptidase mediates the neurofibrillary pathology in Alzheimer’s disease. Nat. Med. 2014, 20, 1254–1262. [CrossRef] [PubMed]
86. Small, S.A.; Duff, K. Linking Abeta and tau in late-onset Alzheimer’s disease: A dual pathway hypothesis. Neuron 2008, 60, 534–542. [CrossRef] [PubMed]
87. Mahmoud, N.N.; Alalbasa, A.; Hikmat, S.; Hamadneh, L.; Zaza, R.; Shraideh, Z.; Khalil, E.A. Nanoparticle size and chemical modification play a crucial role in the interaction of nano gold with the brain: Extent of accumulation and toxicity. Biomater. Sci. 2020, 8, 1669–1682. [CrossRef] [PubMed]
88. He, Z.; Guo, J.L.; McBride, J.D.; Narasimhan, S.; Kim, H.; Changolkar, L.; Zhang, B.; Gathagan, R.J.; Yue, C.; Dengler, C.; et al. Amyloid-β plaques enhance Alzheimer’s brain tau-seeded pathologies by facilitating neuritic plaque tau aggregation. Nat. Med. 2018, 24, 29–38. [CrossRef] [PubMed]
89. Braak, H.; Braak, E. Neuropathological staging of Alzheimer-related changes. Acta Neuropathol. 1991, 82, 239–259. [CrossRef] [PubMed]
90. Arriagada, J.V.; Growdon, J.H.; Hedley-Whyte, E.T.; Hyman, B.T. Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer’s disease. Neurology 1992, 42, 631–639. [CrossRef]
91. Bierer, L.M.; Hof, P.R.; Purohit, D.P.; Carlin, L.; Schmeidler, J.; Davis, K.L.; Perl, D.P. Neocortical neurofibrillary tangles correlate with dementia severity in Alzheimer’s disease. Arch. Neurol. 1995, 52, 81–88. [CrossRef]
92. Hansen, D.V.; Palmer, A.M.; Snape, M.; Wilcock, G.K. The cholinergic hypothesis of Alzheimer’s disease: A review of progress. J. Neurol. Neurosurg. Psychiatry 1999, 66, 137–147. [CrossRef] [PubMed]
93. Francis, P.T.; Palmcr, A.M.; Snape, M.; Wilcock, G.K. The cholinergic hypothesis of Alzheimer’s disease: A review of progress. J. Neurol. Neurosurg. Psychiatry 2003, 74, 1495–1500. [CrossRef] [PubMed]
94. Kahn, A.; Gauthier, S.; Arzberger, T.; Brendel, M.; Kleinberger, G.; Deussing, M.; Focke, C.; Nuscher, B.; Xiong, M.; Ghasemigharagoz, A.; Katzmarski, N.; et al. Loss of TREM2 function increases amyloid seeding but reduces plaque-associated ApoE. Nat. Neurosci. 2019, 22, 191–204. [CrossRef] [PubMed]
95. Kolbo, D.E.; et al. Alzheimer’s disease. Lancet 1976, 2, 1403. [CrossRef] [PubMed]
96. Perry, E.K.; Gibson, P.H.; Blessed, G.; Perry, R.H.; Tomlinson, B.E. Neurotransmitter enzyme abnormalities in senile dementia. Choline acetyltransferase and glutamic acid decarboxylase activities in necropsy brain tissue. J. Neurol. Sci. 1977, 34, 247–265. [CrossRef] [PubMed]
97. Rylett, R.J.; Ball, M.J.; Colhoun, E.H. Evidence for high affinity choline transport in synaptosomes prepared from hippocampus and neocortex of patients with Alzheimer’s disease. Brain Res. 1983, 289, 169–175. [CrossRef] [PubMed]
98. Nilsson, L.; Nordberg, A.; Hardy, J.; Wester, P.; Winblad, B. Phosphostigmone restores 3H-acetylcholine efflux from Alzheimer brain slices to normal level. J. Neuro. Transm. 1986, 78, 275–285. [CrossRef] [PubMed]
99. Burns, A.; Whitehouse, P.; Arendt, T.; Förstl, H. Alzheimer’s disease in senile dementia: Loss of neurones in the basal forebrain. Whitehouse, P., Price, D., Struble, R., Clarke, A., Coyle, J. and Delong, M. Science (1982), 215, 1237–1239. [CrossRef] [PubMed]
100. Davies, P.; Maloney, A.J. Selective loss of central cholinergic neurons in Alzheimer’s disease. Lancet 1976, 2, 1403. [CrossRef] [PubMed]
101. Perry, E.K.; Gibson, P.H.; Blessed, G.; Perry, R.H.; Tomlinson, B.E. Neurotransmitter enzyme abnormalities in senile dementia. Choline acetyltransferase and glutamic acid decarboxylase activities in necropsy brain tissue. J. Neurol. Sci. 1977, 34, 247–265. [CrossRef] [PubMed]
102. Drachman, D.A.; Leavitt, J. Human memory and the cholinergic system. A relationship to aging? Arch. Neurol. 1974, 30, 113–121. [CrossRef] [PubMed]
103. Ferreira-Vieira, T.H.; Guimarães, I.M.; Silva, F.R.; Ribeiro, F.M. Alzheimer’s disease: Targeting the Cholinergic System. Curr. Neuropharmacol. 2016, 14, 101–115. [CrossRef] [PubMed]
104. Truscott, R.T.; Dean, R.L., 3rd; Beer, B.; Lippa, A.S. The cholinergic hypothesis of geriatric memory dysfunction. Science 1982, 217, 408–414. [CrossRef] [PubMed]
105. Ionescu-Tucker, A.; Cotman, C.W. Emerging roles of oxidative stress in brain aging and Alzheimer’s disease. Neurobiol. Aging 2021, 107, 86–95. [CrossRef]
131. Montagne, A.; Nation, D.A.; Sagare, A.P.; Barisano, G.; Sweeney, M.D.; Chakhoyan, A.; Pachicano, M.; Joe, E.; Nelson, A.R.; D’Orazio, L.M.; et al. APOE4 leads to blood-brain barrier dysfunction predicting cognitive decline. Nature 2020, 581, 71–76. [CrossRef] [PubMed]

132. Belaidi, A.; Bush, A.I. Iron neurochemistry in Alzheimer’s disease and Parkinson’s disease: Targets for therapeutics. J. Neurochem. 2016, 139 (Suppl. 1), 179–197. [CrossRef] [PubMed]

133. Xiao, T.; Zhang, W.; Jiao, B.; Pan, C.Z.; Liu, X.; Shen, L. The role of exosomes in the pathogenesis of Alzheimer’ disease. Transl. Neurodegener. 2017, 6, 3. [CrossRef] [PubMed]

134. Van Cauwenberghé, C.; Van Broeckhoven, C.; Sleegers, K. The genetic landscape of Alzheimer disease: Clinical implications and perspectives. Genet. Med. 2016, 18, 421–430. [CrossRef]

135. Matthews, K.A.; Xu, W.; Gaglioti, A.H.; Holt, J.B.; Croft, J.B.; Mack, D.; McGuire, L.C. Racial and ethnic estimates of Alzheimer’s disease and related dementias in the United States (2015-2060) in adults aged ≥65 years. Alzheimers Dement. 2019, 14, 15, 7–24. [CrossRef]

136. Pereira Diniz, L.; Tortelli, V.; Mattias, I.; Morgado, J.; Berghamo Araujo, A.P.; Melo, H.M.; Seixas da Silva, G.S.; Alves-Leon, S.V.; de Souza, J.M.; Ferreira, S.T.; et al. Astrocyte Transforming Growth Factor Beta 1 Protects Synapses against Aβ Oligomers in Alzheimer’s Disease Model. J. Neurosci. 2017, 37, 6797–6809. [CrossRef]

137. Carmona, S.; Hardy, J.; Guerreiro, R. The genetic landscape of Alzheimer disease. Handb. Clin. Neurol. 2018, 148, 395–408. [CrossRef]

138. Bai, B.; Vanderwall, D.; Li, Y.; Wang, X.; Poudel, S.; Wang, H.; Dey, K.K.; Chen, P.C.; Yang, K.; Peng, J. Proteomic landscape of Alzheimer’s Disease: Novel insights into pathogenesis and biomarker discovery. Mol. Neurodegener. 2021, 16, 55. [CrossRef] [PubMed]

139. Dautaj, A.; Mandar

140. Ayodele, T.; Rogaeva, E.; Kurup, J.T.; Beecham, G.; Reitz, C. Early-Onset Alzheimer’s Disease: What Is Missing in Research? Curr. Alzheimer Res. 2016, 13, 2–6. [CrossRef]

141. D’Orazio, L.M.; et al. APOE4 leads to blood-brain barrier dysfunction predicting cognitive decline. Nature 2020, 581, 71–76. [CrossRef] [PubMed]

142. Folstein, M.F.; Folstein, S.E.; McHugh, P.R. “Mini-mental state”: A practical method for grading the cognitive state of patients for the clinician. J. Psychiatr. Res. 1975, 12, 189–198. [CrossRef]

143. Sabbagh, M.N.; Lue, L.-F.; Fayard, D.; Shi, J. Increasing Precision of Clinical Diagnosis of Alzheimer’s Disease Using a Combined Algorithm Incorporating Clinical and Novel Biomarker Data. Neurol. Ther. 2017, 6, 83–95. [CrossRef]
163. Mill, J. Toward an integrated genetic and epigenetic approach to Alzheimer’s disease. *Neurobiol. Aging* 2011, 32, 1188–1191. [CrossRef]

164. Mastromeni, D.; McKee, A.; Grover, A.; Rogers, J.; Coleman, P.D. Epigenetic differences in cortical neurons from a pair of monozygotic twins discordant for Alzheimer’s disease. *PLoS ONE* 2009, 4, e6617. [CrossRef] [PubMed]

165. Mastromeni, D.; Grover, A.; Delvaux, E.; Whiteside, C.; Coleman, P.D.; Rogers, J. Epigenetic changes in Alzheimer’s disease: Decrements in DNA methylation. *Neurobiol. Aging* 2010, 31, 2025–2037. [CrossRef] [PubMed]

166. Lunnon, K.; Mill, J. Epigenetic studies in Alzheimer’s disease: Current findings, caveats, and considerations for future studies. *Am. J. Med. Genet. B: Neuropsychiatr. Genet.* 2013, 162, 789–799. [CrossRef]

167. Sanchez-Mut, J.V.; Graff, J. Epigenetic alterations in Alzheimer’s disease. *Front. Behav. Neurosci.* 2015, 9, 347. [CrossRef]

168. Lord, J.; Cruchaga, C. The epigenetic landscape of Alzheimer’s disease. *Nat. Neurosci.* 2014, 17, 1138–1140. [CrossRef] [PubMed]

169. Chouliaras, L.; Rutten, B.P.; Kenis, G.; Peerbooms, O.; Visser, P.J.; Verhey, F.; van Os, J.; Steinbusch, H.W.; van den Hove, D.L. Epigenetic regulation in the pathophysiology of Alzheimer’s disease. *Prog. Neurobiol.* 2010, 90, 498–510. [CrossRef] [PubMed]

170. Nativio, R.; Lan, Y.; Donahue, G.; Sidoli, S.; Berson, A.; Sririvasan, A.R.; Shecherbakova, O.; Amlie-Wolf, A.; Nie, J.; Cui, X.; et al. An integrated multi-omics approach identifies epigenetic alterations associated with Alzheimer’s disease. *Nat. Genet.* 2020, 52, 1024–1035. [CrossRef]

171. Liu, X.; Jiao, B.; Shen, L. The Epigenetics of Alzheimer’s Disease: Factors and Therapeutic Implications. *Front. Genet.* 2018, 9, 579. [CrossRef]

172. Cheng, Y.; Bernstein, A.; Chen, D.; Jin, P. 5-Hydroxymethylcytosine: A new player in brain disorders? *Exp. Neurol.* 2015, 268, 3–9. [CrossRef] [PubMed]

173. Condiliffe, D.; Wong, A.; Troakes, C.; Proitsi, P.; Patel, Y.; Chouliaras, L.; Fernandes, C.; Cooper, J.; Lovestone, S.; Schalkwyk, L.; et al. Cross-region reduction in 5-hydroxymethylcytosine in Alzheimer’s disease brain. *Neurobiol. Aging* 2014, 35, 1850–1854. [CrossRef]

174. Pishva, E.; Creese, B.; Smith, A.R.; Viechtbauer, W.; Proitsi, P.; van den Hove, D.L.A.; Ballard, C.; Mill, J.; Lunnon, K. Psychosis-associated DNA methylation variation in Alzheimer’s disease cortex. *Neurobiol. Aging* 2020, 89, 83–88. [CrossRef] [PubMed]

175. Cui, D.; Xu, X. DNA Methyltransferases, DNA Methylation, and Age-Associated Cognitive Function. *Int. J. Mol. Sci.* 2018, 19, 1315. [CrossRef]

176. Lee, E.G.; Tulloch, J.; Chen, S.; Leong, L.; Saxton, A.D.; Kraemer, B.; Darvas, M.; Keene, C.D.; Shutes-David, A.; Todd, K.; et al. Redefining transcriptional regulation of the APOE gene and its association with Alzheimer’s disease. *PLoS ONE* 2020, 15, e0227667. [CrossRef] [PubMed]

177. Tulloch, J.; Leong, L.; Thomson, Z.; Chen, S.; Lee, E.-G.; Keene, C.D.; Millard, S.P.; Yu, C.-E. Glia-specific APOE epigenetic changes in the Alzheimer’s disease brain. *Brain Res.* 2018, 1698, 179–186. [CrossRef] [PubMed]

178. Shao, Y.; Shaw, M.; Todd, K.; Khrestian, M.; D’Aleo, G.; Barnard, P.J.; Zahratka, J.; Pillai, J.; Yu, C.-E.; Keene, C.D.; et al. DNA methylation of TOMM40-APOE-APOC2 in Alzheimer’s disease. *J. Hum. Genet.* 2018, 63, 459–471. [CrossRef]

179. Foraker, J.; Millard, S.P.; Leong, L.; Thomson, Z.; Chen, S.; Keene, C.D.; Bekris, L.M.; Yu, C.-E. The APOE Gene is Differentially Methyalted in Alzheimer’s Disease. *J. Alzheimers Dis.* 2015, 48, 745–755. [CrossRef]

180. Mur, J.; McCartney, D.L.; Walker, R.M.; Campbell, A.; Beringham, M.L.; Morris, S.W.; Forteous, D.J.; McIntosh, A.M.; Deary, I.J.; Evans, K.L.; et al. DNA methylation in APOE: The relationship with Alzheimer’s and with cardiovascular health. *Alzheimers Dement.* 2020, 6, e10206. [CrossRef]

181. Misu, A.; Yoshino, Y.; Yamazaki, K.; Ozaki, Y.; Sato, T.; Yoshida, T.; Mori, T.; Mori, Y.; Ochi, S.; Iga, J.-I.; et al. TOMM40 and APOE Gene Expression and Cognitive Decline in Japanese Alzheimer’s Disease Subjects. *J. Alzheimer Dis.* 2017, 60, 1107–1117. [CrossRef] [PubMed]

182. Nicolia, V.; Ciraci, V.; Cavallaro, R.A.; Ferrer, I.; Scarpa, S.; Fusco, A. GSK3β 5′-flanking DNA Methylation and Expression in Alzheimer’s Disease Patients. *Curr. Alzheimer Res.* 2015, 12, 753–759. [CrossRef]

183. Huang, Y.; Sun, X.; Jiang, H.; Yu, S.; Robins, C.; Armstrong, M.J.; Li, R.; Mei, Z.; Shi, X.; Gerasimov, E.S. A machine learning approach to brain epigenetic analysis reveals kinases associated with Alzheimer’s disease. *Nat. Commun.* 2021, 12, 1–12. [CrossRef] [PubMed]

184. Smith, A.R.; Smith, R.G.; Burrage, J.; Troakes, C.; Al-Sarraj, S.; Kalaria, R.N.; Sloan, C.; Robinson, A.C.; Mill, J.; Lunnon, K. A cross-brain regions study of ANK1 DNA methylation in different neurodegenerative diseases. *Neurobiol. Aging* 2019, 74, 70–76. [CrossRef] [PubMed]

185. Nagata, T.; Kobayashi, N.; Ishii, J.; Shinagawa, S.; Nakayama, R.; Shibata, N.; Kuerban, B.; Ohnuma, T.; Kondo, K.; Arai, H.; et al. Association between DNA Methylation of the BDNF Promoter Region and Clinical Presentation in Alzheimer’s Disease. *Dement. Geriatr. Cogn. Dis. Extra* 2015, 5, 64–73. [CrossRef]

186. Smith, A.R.; Smith, R.G.; Pishva, E.; Hannon, E.; Roubroeks, J.A.Y.; Burrage, J.; Troakes, C.; Al-Sarraj, S.; Sloan, C.; Mill, J.; et al. Parallel profiling of DNA methylation and hydroxymethylation highlights neuropathology-associated epigenetic variation in Alzheimer’s disease. *Clin. Epigenetics* 2019, 11, 52. [CrossRef] [PubMed]

187. Semick, S.A.; Bharadwaj, R.A.; Collado-Torres, L.; Tao, R.; Shin, J.H.; Deep-Soboslay, A.; Weiss, J.R.; Weinberger, D.R.; Hyde, T.M.; Kleinman, J.E.; et al. Integrated DNA methylation and gene expression profiling across multiple brain regions implicate novel genes in Alzheimer’s disease. *Acta Neuropathol.* 2019, 137, 557–569. [CrossRef] [PubMed]
188. Lunnon, K.; Smith, R.; Hannon, E.; De Jager, P.L.; Srivastava, G.; Volta, M.; Troakes, C.; Al-Sarraj, S.; Burrage, J.; Macdonald, R.; et al. Methylation profiling implicates cortical deregulation of ANK1 in Alzheimer’s disease. *Nat. Neurosci.* 2014, 17, 1164–1170. [CrossRef] [PubMed]

189. De Jager, P.L.; Srivastava, G.; Lunnon, K.; Burgess, J.; Schalkwyk, L.C.; Yu, L.; Eaton, M.L.; Keenan, B.T.; Ernst, J.; McCabe, C.; et al. Alzheimer’s disease: Early alterations in brain DNA methylation at ANK1, BIN1, RHBDF2 and other loci. *Nat. Neurosci.* 2014, 17, 1156–1163. [CrossRef]

190. Villela, D.; Ramalho, R.F.; Silva, A.R.; Brentani, H.; Suemoto, C.K.; Pasqualetti, C.A.; Grinberg, L.T.; Krepisc, A.; Rosenberg, C. Differential DNA Methylation of MicroRNA Genes in Temporal Cortex from Alzheimer’s Disease Individuals. *Neural Plast.* 2016, 2016, 2584940. [CrossRef]

191. Watson, C.T.; Roussos, P.; Garg, P.; Ho, D.J.; Azam, N.; Katsel, P.L.; Haroutunian, V.; Sharp, A.J. Genome-wide DNA methylation profiling in the superior temporal gyrus reveals epigenetic signatures associated with Alzheimer’s disease. *Genome Med.* 2016, 8, 5. [CrossRef]

192. Li, P.; Marshall, L.; Oh, G.; Jakubowski, J.L.; Groot, D.; He, Y.; Wang, T.; Petronis, A.; Labrie, V. Epigenetic dysregulation of enhancers in neurons is associated with Alzheimer’s disease pathology and cognitive symptoms. *Nat. Commun.* 2019, 10, 2246. [CrossRef]

193. Andrés-Beníto, P.; Delgado-Morales, R.; Ferrer, I. Altered regulation of KIAA0566, and katanin signaling expression in the locus coeruleus with neurofibrillary tangle pathology. *Front. Cell. Neurosci.* 2018, 12, 131. [CrossRef]

194. Madrid, A.; Hogan, K.J.; Papale, L.A.; Clark, L.R.; Asthana, S.; Johnson, S.C.; Alisch, R.S. DNA Hypomethylation in Blood Links B3GALT4 and ZADH2 to Alzheimer’s Disease. *J. Alzheimer Dis.* 2018, 66, 927–934. [CrossRef] [PubMed]

195. Stanga, S.; Caretto, A.; Boido, M.; Vercelli, A. Mitochondrial Dysfunctions: A Red Thread across Neurodegenerative Diseases. *Int. J. Mol. Sci.* 2020, 21, 3719. [CrossRef] [PubMed]

196. Rey, F.; Ottolenghi, S.; Zuccotti, G.V.; Samaja, M.; Carelli, S. Mitochondrial dysfunctions in neurodegenerative diseases: Role in disease pathogenesis, strategies for analysis and therapeutic prospects. *Neural. Regen. Res.* 2022, 17, 754–758. [CrossRef] [PubMed]

197. Stoccoro, A.; Siciliano, G.; Migliore, L.; Coppèdè, F. Decreased Methylation of the Mitochondrial D-Loop Region in Late-Onset Alzheimer’s Disease. *J. Alzheimer Dis.* 2017, 59, 599–564. [CrossRef] [PubMed]

198. Strobel, S.; Grünblatt, E.; Heinsen, H.; Riederer, P.; Espach, T.; Meder, M.; Monoranu, C.M. Astrocyte- and Microglia-Specific Mitochondrial DNA Deletions Levels in Sporadic Alzheimer’s Disease. *J. Alzheimers Dis.* 2019, 67, 149–157. [CrossRef]

199. Miller, B.; Kim, S.J.; Mehta, H.H.; Cao, K.; Kumagai, H.; Thumaty, N.; Leelaprachakul, N.; Jiao, H.; Vaughan, J.; Diedrich, J.; et al. Mitochondrial DNA variation in Alzheimer’s disease reveals a unique microprotein called SHMOOSE. *Mol. Psychiatry* 2020, 25, 559–564. [CrossRef] [PubMed]

200. Coskun, P.; Figueiro-Silva, J.; Llado, A.; Molinero, F. Decreased Methylation of the Mitochondrial D-Loop Region in Late-Onset Alzheimer’s Disease. *J. Alzheimer Dis.* 2018, 59, 1787–1792. [CrossRef] [PubMed]

201. Coskun, P.; Figureiro-Silva, J.; Llado, A.; Antonell, A.; Sanchez-Valle, R.; Alcolea, D.; Lleo, A.; Molinero, F.; Leelaprachakul, N.; Jiao, H.; Vaughan, J.; Diedrich, J.; et al. Mitochondrial DNA variation in Alzheimer’s disease reveals a unique microprotein called SHMOOSE. *Mol. Psychiatry* 2020, 25, 559–564. [CrossRef] [PubMed]

202. Coskun, P.; Figureiro-Silva, J.; Llado, A.; Antonell, A.; Sanchez-Valle, R.; Alcolea, D.; Lleo, A.; Molinero, F.; Leelaprachakul, N.; Jiao, H.; Vaughan, J.; Diedrich, J.; et al. Mitochondrial DNA variation in Alzheimer’s disease reveals a unique microprotein called SHMOOSE. *Mol. Psychiatry* 2020, 25, 559–564. [CrossRef] [PubMed]

203. Podlesny, P.; Puigros, M.; Serra, N.; Sepúlveda-Falla, D.; Schmidt, C.; Hermann, P.; Zerr, I.; Trullas, R. Cerebrospinal Fluid Mitochondrial DNA in Rapid and Slow Progressive Forms of Alzheimer’s Disease. *Int. J. Mol. Sci.* 2020, 21, 6298. [CrossRef] [PubMed]

204. Podlesny, P.; Puigros, M.; Serra, N.; Sepúlveda-Falla, D.; Schmidt, C.; Hermann, P.; Zerr, I.; Trullas, R. Cerebrospinal Fluid Mitochondrial DNA in Rapid and Slow Progressive Forms of Alzheimer’s Disease. *Int. J. Mol. Sci.* 2020, 21, 6298. [CrossRef] [PubMed]

205. Podlesny, P.; Puigros, M.; Serra, N.; Sepúlveda-Falla, D.; Schmidt, C.; Hermann, P.; Zerr, I.; Trullas, R. Cerebrospinal Fluid Mitochondrial DNA in Rapid and Slow Progressive Forms of Alzheimer’s Disease. *Int. J. Mol. Sci.* 2020, 21, 6298. [CrossRef] [PubMed]

206. Blanch, M.; Mosquera, J.L.; Ansoleaga, B.; Ferrer, I.; Barrachina, M. Altered Mitochondrial DNA Methylation Pattern in Alzheimer Disease-Related Pathology and in Parkinson Disease. *Am. J. Pathol.* 2016, 186, 385–397. [CrossRef] [PubMed]

207. Ellison, E.M.; Bradley-Whitman, M.E.; Lovell, M.A.; Lovell, M.A.; Lovell, M.A.; Lovell, M.A. Single-Base Resolution Mapping of 5-Hydroxymethylcytosine Modifications in Hippocampus of Alzheimer’s Disease Subjects. *J. Mol. Neurosci.* 2017, 63, 185–197. [CrossRef]

208. Zhao, J.; Zhu, Y.; Yang, J.; Li, L.; Wu, H.; De Jager, P.L.; Jin, P.; Bennett, D.A. A genome-wide profiling of brain DNA hydroxymethylation in Alzheimer’s disease. *Alzheimers Dement.* 2017, 13, 674–688. [CrossRef] [PubMed]

209. Bernstein, A.L.; Lin, Y.; Street, R.C.; Lin, L.; Dai, Q.; Yu, L.; Bao, H.; Gearing, M.; Lah, J.J.; Nelson, P.T.; et al. 5-Hydroxymethylation-associated epigenetic modifiers of Alzheimer’s disease modulate Tau-induced neurotoxicity. *Hum. Mol. Genet.* 2016, 25, 2437–2450. [CrossRef] [PubMed]

210. Orre, M.; Kamphuis, W.; Osborn, L.M.; Jansen, A.H.P.; Kooijman, L.; Bossers, K.; Hol, E.M. Isolation of glia from Alzheimer’s mice reveals inflammation and dysfunction. *Neurobiol. Aging* 2014, 35, 2746–2760. [CrossRef]

211. Chouliaras, L.; Mastroeni, D.; Delvaux, E.; Grover, A.; Kenis, G.; Hof, P.R.; Steinbusch, H.W.; Coleman, P.D.; Rutten, B.P.; van den Hove, D.L. Consistent decrease in global DNA methylation and hydroxymethylation in the hippocampus of Alzheimer’s disease patients. *Neurobiol. Aging* 2013, 34, 2091–2099. [CrossRef] [PubMed]
212. Coppoeters, N.; Dierikx, B.V.; Lill, C.; Faul, R.L.M.; Curtis, M.A.; Dragunow, M. Global changes in DNA methylation and hydroxymethylation in Alzheimer’s disease human brain. *Neurobiol. Aging* 2014, 35, 1334–1344. [CrossRef]

213. Phipps, A.J.; Vickers, J.C.; Taberlay, P.C.; Woodhouse, A. Neurofilament-labeled pyramidal neurons and astrocytes are deficient in DNA methylation marks in Alzheimer’s disease. *Neurobiol. Aging* 2016, 45, 30–42. [CrossRef]

214. Lashley, T.; Gami, P.; Valizadeh, N.; Li, A.; Revesz, T.; Balazs, R. Alterations in global DNA methylation and hydroxymethylation are not detected in Alzheimer’s disease. *Neuropathol. Appl. Neurobiol.* 2015, 41, 497–506. [CrossRef] [PubMed]

215. Celarain, N.; Sánchez-Ruiz de Gordoa, J.; Zelaya, M.V.; Roldán, M.; Larumbe, R.; Pulufo, L.; Echavarri, C.; Mendioroz, M. TREM2 upregulation correlates with 5-hydroxymethylcytosine enrichment in Alzheimer’s disease hippocampus. *Clin. Epigenetics* 2016, 8, 37. [CrossRef] [PubMed]

216. Strahl, B.D.; Allis, C.D. The language of covalent histone modifications. *Nature* 2000, 403, 41–45. [CrossRef]

217. Wang, J.; Yu, J.-T.; Tan, M.-S.; Jiang, T.; Tan, L. Epigenetic mechanisms in Alzheimer’s disease: Implications for pathogenesis and therapy. *Aging Res. Rev.* 2013, 12, 1024–1041. [CrossRef]

218. Berson, A.; Nativio, R.; Berger, S.L.; Bonini, N.M. Epigenetic Regulation in Neurodegenerative Diseases. *Trends Neurosci.* 2018, 41, 587–598. [CrossRef]

219. Frost, B.; Hemberg, M.; Lewis, J.; Feany, M.B. Tau promotes neurodegeneration through global chromatin relaxation. *Nat. Neurosci.* 2014, 17, 357–366. [CrossRef] [PubMed]

220. Lu, X.; Wang, L.; Yu, C.; Yu, D.; Yu, G. Histone Acetylation Modifiers in the Pathogenesis of Alzheimer’s Disease. *Front. Cell. Neurosci.* 2015, 9, 226. [CrossRef]

221. MacBean, L.F.; Smith, A.R.; Lunnon, K. Exploring Beyond the DNA Sequence: A Review of Epigenomic Studies of DNA and Protein Interactions in Dementia. *Curr. Genet. Med. Rep.* 2020, 17, 79–92. [CrossRef]

222. Klein, H.-U.; McCabe, C.; Gjoneska, E.; Sullivan, S.E.; Kaskow, B.J.; Tang, A.; Smith, R.V.; Xu, J.; Pfenning, A.R.; Bernstein, B.E.; et al. Epigenome-wide study uncovers large-scale changes in histone acetylation driven by tau pathology in aging and Alzheimer’s human brains. *Nat. Neurosci.* 2019, 22, 37–46. [CrossRef]

223. Marzi, S.J.; Leung, S.K.; Ribarska, T.; Hannon, E.; Smith, A.R.; Pishva, E.; Poschmann, J.; Moore, K.; Troakes, C.; Al-Sarraj, S.; et al. A histone acetylome-wide association study of Alzheimer’s disease identifies disease-associated H3K27ac differences in the entorhinal cortex. *Nat. Neurosci.* 2018, 21, 1618–1627. [CrossRef]

224. Zhang, K.; Schrag, M.; Crofton, A.; Trivedi, R.; Vinters, H.; Kirsch, W. Targeted proteomics for quantification of histone acetylation in Alzheimer’s disease. *Proteomics* 2012, 12, 1261–1268. [CrossRef] [PubMed]

225. Narayan, P.J.; Lil, C.; Faul, R.; Curtis, M.A.; Dragunow, M. Increased acetyl and total histone levels in post-mortem Alzheimer’s disease brain. *Neurobiol. Dis.* 2015, 74, 281–294. [CrossRef] [PubMed]

226. Ding, H.; Dolan, P.J.; Johnson, G.V.W. Histone deacetylase 6 interacts with the microtubule-associated protein tau. *J. Neurochem.* 2008, 106, 2119–2130. [CrossRef] [PubMed]

227. Konsonoul, Z.; Barile, F.A. Epigenetic histone acetylation and deacetylation mechanisms in experimental models of neurodegenerative disorders. *J. Pharmacol. Toxicol. Methods* 2012, 66, 215–220. [CrossRef] [PubMed]

228. Zhang, L.; Sheng, S.; Qin, C. The role of HDACs in Alzheimer’s disease. *J. Alzheimers Dis.* 2013, 33, 283–295. [CrossRef] [PubMed]

229. Xu, K.; Dai, X.L.; Huang, H.C.; Jiang, Z.F. Targeting HDACs: A promising therapy for Alzheimer’s disease. *Oxid. Med. Cell. Longev.* 2011, 2011, 143269. [CrossRef]

230. Fischer, A. Targeting histone-modifications in Alzheimer’s disease. What is the evidence that this is a promising therapeutic avenue? *Neuropsychobiology* 2014, 80, 95–102. [CrossRef]

231. Ryu, H.; Barrup, M.; Kowall, N.W.; McKee, A.C. P3-260: Epigenetic modification in a monozygotic twin with Alzheimer’s disease. *Alzheimer Dement.* 2008, 4, T598. [CrossRef]

232. Coneys, R.; Wood, I.C. Alzheimer’s disease: The potential of epigenetic treatments and current clinical candidates. *Neurodegener. Dis. Manag.* 2020, 10, 543–558. [CrossRef]

233. Ogawa, O.; Zhu, X.; Lee, H.G.; Raina, A.; Obrenovich, M.E.; Bowser, R.; Ghanbari, H.A.; Castellani, R.J.; Perry, G.; Smith, M.A. Ectopic localization of phosphorylated histone H3 in Alzheimer’s disease: A mitotic catastrophe? *Acta Neuropathol.* 2003, 105, 524–528. [CrossRef]

234. Myung, N.H.; Zhu, X.; Kruman, I.I.; Castellani, R.J.; Petersen, R.B.; Siedlak, S.L.; Perry, G.; Smith, M.A.; Lee, H.G. Evidence of DNA damage in Alzheimer disease: Phosphorylation of histone H2AX in astrocytes. *Age* 2008, 30, 209–215. [CrossRef] [PubMed]

235. Love, S.; Barber, R.; Wilcock, G.K. Increased poly(ADP-ribosyl)ation of nuclear proteins in Alzheimer’s disease. *Brain* 1999, 122 Pt 2, 247–253. [CrossRef] [PubMed]

236. Millan, M.J. Linking deregulation of non-coding RNA to the core pathophysiology of Alzheimer’s disease: An integrative review. *Prog. Neurobiol.* 2017, 156, 1–68. [CrossRef] [PubMed]

237. Das, U.; Wang, L.; Ganguy, A.; Saikia, J.M.; Wagner, S.L.; Koo, E.H.; Roy, S. Visualizing APP and BACE-1 approximation in neurons yields insight into the amyloidogenic pathway. *Nat. Neurosci.* 2016, 19, 55–64. [CrossRef] [PubMed]

238. Long, J.M.; Ray, B.; Lahiri, D.K. MicroRNA-339-5p down-regulates protein expression of β-site amyloid precursor protein-cleaving enzyme 1 (BACE1) in human primary brain cultures and is reduced in brain tissue specimens of Alzheimer disease subjects. *J. Biol. Chem.* 2014, 289, 5184–5198. [CrossRef]

239. Selkoe, D.J.; Hardy, J. The amyloid hypothesis of Alzheimer’s disease at 25 years. *EMBO J. Mol. Med.* 2016, 8, 595–608. [CrossRef]
240. Zhang, Y.; Xing, H.; Guo, S.; Zheng, Z.; Wang, H.; Xu, D. MicroRNA-135b has a neuroprotective role via targeting of β-site APP-cleaving enzyme 1. *Exp. Ther. Med.* **2016**, *12*, 809–814. [CrossRef]

241. Banzhaf-Strathmann, J.; Benito, E.; May, S.; Arzberger, T.; Tahirovic, S.; Kretzschmar, H.; Fischer, A.; Edbauer, D. MicroRNA-125b induces tau hyperphosphorylation and cognitive deficits in Alzheimer’s disease. *EMBO J.* **2014**, *33*, 1667–1680. [CrossRef]

242. Ma, X.; Liu, L.; Meng, J. MicroRNA-125b promotes neurons cell apoptosis and Tau phosphorylation in Alzheimer’s disease. *Neurosci. Lett.* **2017**, *661*, 57–62. [CrossRef]

243. Zhou, Y.; Deng, J.; Chu, X.; Zhao, Y. Role of Post-Transcriptional Control of Calpain by miR-124-3p in the Development of Alzheimer’s Disease. *J. Alzheimer’s Dis.* **2019**, *67*, 571–581. [CrossRef]

244. Remenyi, J.; Hunter, C.J.; Cole, C.; Ando, H.; Impey, S.; Monk, C.E.; Martin, K.J.; Barton, G.J.; Hutvagner, G.; Arthur, J.S. Regulation of the miR-212/132 locus by MSK1 and CREB in response to neurotoxins. *Biochem. J.* **2010**, *428*, 281–291. [CrossRef] [PubMed]

245. Pichler, S.; Gu, W.; Hartl, D.; Gasparoni, G.; Leidinger, P.; Keller, A.; Meese, E.; Mayhaus, M.; Hampel, H.; Riemenschneider, M. The miRNome of Alzheimer’s disease: Consistent downregulation of the miR-132/212 cluster. *Neurobiol. Aging* **2017**, *50*, 167.e1–167.e10. [CrossRef] [PubMed]

246. Kawashima, H.; Numakawa, T.; Kumanamaru, E.; Adachi, N.; Mizuno, H.; Ninomiya, M.; Kunugi, H.; Hashido, K. Glucocorticoid attenuates brain-derived neurotrophic factor-dependent upregulation of glutamate receptors via the suppression of microRNA-132 expression. *Neuroscience* **2010**, *165*, 1301–1311. [CrossRef] [PubMed]

247. Subramanian, M.; Hyeon, S.J.; Das, T.; Suh, Y.S.; Kim, Y.K.; Lee, J.S.; Song, E.J.; Ryu, H.; Yu, K. UBE4B, a microRNA-9 target gene, promotes autophagy-mediated Tau degradation. *Nat. Commun.* **2021**, *12*, 3291. [CrossRef] [PubMed]

248. Yuva-Aydemir, Y.; Simkin, A.; Gascon, E.; Gao, F.B. MicroRNA-9: Functional evolution of a conserved small regulatory RNA. *RNA Biol.* **2011**, *8*, 557–564. [CrossRef] [PubMed]

249. Hokohan, K.N.; Lahiri, D.K.; Schneider, B.P.; Foroud, T.; Saykin, A.J. Functional microRNAs in Alzheimer’s disease and cancer: Differential regulation of common mechanisms and pathways. *Front. Genet.* **2012**, *3*, 323. [CrossRef] [PubMed]

250. Miya Shaik, M.; Tamargo, I.A.; Abubakar, M.B.; Kamal, M.A.; Greig, N.H.; Gan, S.H. The Role of microRNAs in Alzheimer’s Disease and Their Therapeutic Potentials. *Genes* **2018**, *9*, 174. [CrossRef] [PubMed]

251. Chang, F.; Zhang, L.H.; Xu, W.P.; Jing, P.; Zhan, P.Y. microRNA-9 attenuates amyloid precursor protein-cleaving enzyme 1. *Brain Res.* **2011**, *1395*, 108–115. [CrossRef] [PubMed]

252. Shioya, M.; Obayashi, S.; Tabunoki, H.; Arima, K.; Saito, Y.; Ishida, S.; Sato, J. Aberrant microRNA expression in the brains of neurodegenerative diseases: miR-29a decreased in Alzheimer disease brains targets neuropeptide Y 3. *Neuropathol. Appl. Neurobiol.* **2010**, *36*, 320–330. [CrossRef]

253. Dickson, J.R.; Kruse, C.; Montagna, D.R.; Finsen, B.; Wolfe, M.S. Alternative polyadenylation and miR-34 family members regulate tau expression. *J. Neurosci.* **2013**, *127*, 739–747. [CrossRef]

254. Wang, W.X.; Rajeev, B.W.; Stromberg, A.J.; Ren, N.; Tang, G.; Huang, Q.; Rigoutsos, I.; Nelson, P.T. The expression of microRNA miR-107 decreases early in Alzheimer’s disease and may accelerate disease progression through regulation of beta-site amyloid precursor protein-cleaving enzyme 1. *J. Neurosci.* **2008**, *28*, 1213–1223. [CrossRef] [PubMed]

255. Kademakers, R.; Sleeckers, K.; Theuns, J.; Van den Broeck, M.; Bel Kacem, S.; Nilsson, L.G.; Adolphson, R.; van Duijn, C.M.; Van Broeckhoven, C. APP and BACE1 microRNA genetic variability has no major role in risk for Alzheimer disease. *Hum. Mutat.* **2009**, *30*, 1207–1213. [CrossRef] [PubMed]

256. Zong, Y.; Wang, H.; Dong, W.; Quan, X.; Zhu, H.; Xu, Y.; Huang, L.; Ma, C.; Qin, C. miR-29c regulates BACE1 protein expression. *Brain Res.* **2011**, *1355*, 108–115. [CrossRef] [PubMed]

257. Wang, W.X.; Rajeve, B.W.; Stromberg, A.J.; Ren, N.; Tang, G.; Huang, Q.; Rigoutsos, I.; Nelson, P.T. The expression of microRNA miR-107 decreases early in Alzheimer’s disease and may accelerate disease progression through regulation of beta-site amyloid precursor protein-cleaving enzyme 1. *J. Neurosci.* **2008**, *28*, 1213–1223. [CrossRef] [PubMed]

258. Wang, W.X.; Rajeve, B.W.; Stromberg, A.J.; Ren, N.; Tang, G.; Huang, Q.; Rigoutsos, I.; Nelson, P.T. The expression of microRNA miR-107 decreases early in Alzheimer’s disease and may accelerate disease progression through regulation of beta-site amyloid precursor protein-cleaving enzyme 1. *J. Neurosci.* **2008**, *28*, 1213–1223. [CrossRef] [PubMed]

259. Wang, W.X.; Rajeve, B.W.; Stromberg, A.J.; Ren, N.; Tang, G.; Huang, Q.; Rigoutsos, I.; Nelson, P.T. The expression of microRNA miR-107 decreases early in Alzheimer’s disease and may accelerate disease progression through regulation of beta-site amyloid precursor protein-cleaving enzyme 1. *J. Neurosci.* **2008**, *28*, 1213–1223. [CrossRef] [PubMed]

260. Schonrock, N.; Ke, Y.D.; Humphreys, D.; Staufenbiel, M.; Ittner, L.M.; Preiss, T.; Götz, J. Neuronal microRNA deregulation in response to Alzheimer’s disease amyloid-beta. *PloS ONE* **2010**, *5*, e11070. [CrossRef]

261. Lee, S.-T.; Chu, K.; Jung, K.-H.; Kim, J.H.; Huh, J.-Y.; Yoon, H.; Park, D.-K.; Lim, J.-Y.; Kim, J.-M.; Jeon, D.; et al. miR-206 regulates brain-derived neurotrophic factor in Alzheimer disease model. *Ann. Neurol.* **2012**, *72*, 269–277. [CrossRef]

262. McKhann, G.M.; Knopman, D.S.; Chertkow, H.; Hyman, B.T.; Jack, C.R., Jr.; Kawas, C.H.; Klunk, W.E.; Koroshetz, W.J.; Manly, J.J.; Mayeux, R.; et al. The diagnosis of dementia due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. *Alzheimers Dement.* **2011**, *7*, 263–269. [CrossRef] [PubMed]
Albert, M.S.; DeKosky, S.T.; Dickson, D.; Dubois, B.; Feldman, H.H.; Fox, N.C.; Gamst, A.; Holtzman, D.M.; Jagust, W.J.; Petersen, R.C.; et al. The diagnosis of mild cognitive impairment due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement. 2011, 7, 270–279. [CrossRef] [PubMed]

Fodero-Tavoletti, M.T.; Okamura, N.; Furumoto, S.; Mulligan, R.S.; Connor, A.R.; McLean, C.A.; Cao, D.; Rigopoulos, A.; Cartwright, G.A.; O’Keefe, G.; et al. 18F-THK523: A novel in vivo tau imaging ligand for Alzheimer’s disease. Brain 2011, 134, 1089–1100. [CrossRef] [PubMed]

Tzioras, M.; Davies, C.; Newman, A.; Jackson, R.; Spires-Jones, T. Invited Review: APOE at the interface of inflammation, neurodegeneration and pathological protein spread in Alzheimer’s disease. Neuropathol. Appl. Neurobiol. 2019, 45, 327–346. [CrossRef]

Chang, S.-m.; Sung, H.-C.C. The effectiveness of seal-like robot therapy on mood and social interactions of older adults: A systematic review protocol. JBI Evid. Synth. 2013, 11, 68–75. [CrossRef]

González, J.F.; Alcántara, A.R.; Doadrio, A.L.; Sánchez-Montero, J.M. Developments with multi-target drugs for Alzheimer’s disease: An overview of the current discovery approaches. Expert Opin. Drug Discov. 2019, 14, 879–891. [CrossRef]

Jacobson, S.A.; Sabbagh, M.N. Donepezil: Potential neuroprotective and disease-modifying effects. Expert Opin. Drug Metab. Toxicol. 2008, 4, 1563–1569. [CrossRef]

Weinstock, M. Selectivity of Cholinesterase Inhibition. CNS Drugs 1999, 12, 307–323. [CrossRef]

Sharma, K. Cholinesterase inhibitors as Alzheimer’s therapeutics (Review). Mol. Med. Rep. 2019, 20, 1479–1487. [CrossRef]

Breijiyeh, Z.; Karaman, R. Comprehensive Review on Alzheimer’s Disease: Causes and Treatment. Molecules 2020, 25, 5789. [CrossRef]

Bar-On, P.; Millard, C.B.; Harel, M.; Dvir, H.; Enz, A.; Sussman, J.L.; Silman, I. Kinetic and structural studies on the interaction of cholinesterases with the anti-Alzheimer drug rivastigmine. Biochemistry 2002, 41, 3555–3564. [CrossRef] [PubMed]

Folch, J.; Busquets, O.; Etcheto, M.; Sánchez-López, E.; Castro-Torres, R.D.; Verdaguer, E.; García, M.L.; Oloquequi, J.; Casadesús, G.; Beas-Zarate, C.; et al. Memantine for the Treatment of Dementia: A Review on its Current and Future Applications. J. Alzheimers Dis. 2018, 62, 1223–1240. [CrossRef]

Vaz, M.; Silvestre, S. Alzheimer’s disease: Recent treatment strategies. Eur. J. Pharmacol. 2020, 887, 173554. [CrossRef]

Sevigny, J.; Chiao, P.; Bussière, T.; Weinreb, P.H.; Williams, L.; Maier, M.; Dunstan, R.; Salloway, S.; Chen, T.; Ling, Y. The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease. Nature 2021, 563, 50–56. [CrossRef] [PubMed]

Rabinovici, G.D. Controversy and Progress in Alzheimer’s Disease—FDA Approval of Aducanumab. N. Engl. J. Med. 2021, 385, 771–774. [CrossRef]

Mintun, M.A.; Lo, A.C.; Duggan Evans, C.; Wessels, A.M.; Ardayfio, P.A.; Andersen, S.W.; Scherbinin, S.; Sparks, J.; Sims, J.R.; Brys, M.; et al. Donanemab in Early Alzheimer’s Disease. N. Engl. J. Med. 2021, 384, 1691–1704. [CrossRef]

Swanson, C.J.; Zhang, Y.; Dhadda, S.; Wang, J.; Kaplow, J.; Lai, R.Y.K.; Lannfelt, L.; Bradley, H.; Rabe, M.; Koyama, A.; et al. A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer’s disease: An overview of the current discovery approaches. J. Alzheimers Dis. 2018, 62, 1223–1240. [CrossRef]

Marasco, R.A. Current and evolving treatment strategies for the Alzheimer disease continuum. Am. J. Manag. Care 2020, 26, S167–S176. [CrossRef]

West, T.; Hu, Y.; Verghese, P.; Bateman, R.; Braakman, J.; Fogelman, I.; Budur, K.; Florian, H.; Mendonca, N.; Holtzman, D. Preclinical and clinical development of ABBV-8E12, a humanized anti-Aβ antibody, for treatment of Alzheimer’s disease and other tauopathies. J. Prev. Alzheimers Dis. 2017, 4, 236–241. [PubMed]

Qureshi, I.A.; Tirucheri, G.; Ahlijanian, M.K.; Kolattis, G.; Bechtold, C.; Grundman, M. A randomized, single ascending dose study of intravenous BIB092 in healthy participants. Alzheimers Dement. 2018, 4, 746–755. [CrossRef]

Ayalon, G.; Lee, S.H.; Adolfsen, O.; Foo-Atkins, C.; Atwal, J.K.; Blendstrup, M.; Booher, L.; Bravo, J.; Brentza, R.; Brunstein, F.; et al. Antibody semorinemab reduces tau pathology in a transgenic mouse model and engages tau in patients with Alzheimer’s disease. Neurosci. Lett. 2021, 1479–1487. [CrossRef] [PubMed]

Anderson, R.M.; Hadjichrysanthou, C.; Evans, S.; Wong, M.M. Why do so many clinical trials of therapies for Alzheimer’s disease fail? Lancet 2017, 380, 2327–2329. [CrossRef]

Cummings, J.L.; Morstorf, T.; Zhong, K. Alzheimer’s disease drug-development pipeline: Few candidates, frequent failures. Alzheimers Res. Ther. 2014, 6, 37. [CrossRef] [PubMed]

Becker, R.E.; Greig, N.H.; Giacobini, E. Why do so many drugs for Alzheimer’s disease fail in development? Time for new methods and new practices? J. Alzheimers Dis. 2008, 15, 303–325. [CrossRef]

Mehta, D.; Jackson, R.; Paul, G.; Shi, J.; Sabbagh, M. Why do trials for Alzheimer’s disease drugs keep failing? A discontinued drug perspective for 2010-2015. Expert Opin. Investig. Drugs 2017, 26, 735–739. [CrossRef] [PubMed]
Diagnostics 2022, 12, 2975

292. Brown, F.C.; Katz, L.J.; Roth, R.M.; Beers, S.R. The relationship of self-reported subclinical obsessive-compulsive symptoms and impulsivity among adults with AD/HD. *Psychiatry Res.* 2014, 216, 131–136. [CrossRef] [PubMed]

293. Huffman, J.C.; Stern, T.A. Assessment of the Awake but Unresponsive Patient. *Prim. Care Companion. J. Clin. Psychiatry* 2003, 5, 227–231. [CrossRef]

294. Amen, D.G.; Trujillo, M.; Newberg, A.; Willeumier, K.; Tarzwell, R.; Wu, J.C.; Chaitin, B. Brain SPECT Imaging in Complex Psychiatric Cases: An Evidence-Based, Underutilized Tool. *Open Neuroimag. J.* 2011, 5, 40–48. [CrossRef] [PubMed]

295. Pangalos, M.N.; Schechter, L.E.; Hurko, O. Drug development for CNS disorders: Strategies for balancing risk and reducing attrition. *Nat. Rev. Drug Discov.* 2007, 6, 521–532. [CrossRef]

296. Engelhardt, N.; Feiger, A.D.; Cogger, K.O.; Sikich, D.; DeBrota, D.J.; Lipsitz, J.D.; Kobak, K.A.; Evans, K.R.; Potter, W.Z. Rating the raters: Assessing the quality of Hamilton rating scale for depression clinical interviews in two industry-sponsored clinical drug trials. *J. Clin. Psychopharmacol.* 2006, 26, 71–74. [CrossRef] [PubMed]

297. Becker, R.E.; Greig, N.H. Alzheimer’s disease drug development in 2008 and beyond: Problems and opportunities. *Curr. Alzheimer Res.* 2008, 5, 346–357. [CrossRef] [PubMed]

298. Cetin, S.; Knez, D.; Gobec, S.; Kos, J.; Pišlar, A. Cell models for Alzheimer’s and Parkinson’s disease: At the interface of biology and drug discovery. *Biomed. Pharmacother.* 2022, 149, 119294. [CrossRef] [PubMed]

299. Davis, K.L.; Thal, L.J.; Gamzu, E.R.; Davis, C.S.; Woolson, R.F.; Gracon, S.I.; Drachman, D.A.; Schneider, L.S.; Whitehouse, P.J.; Hoover, T.M.; et al. A double-blind, placebo-controlled multicenter study of tacrine for Alzheimer’s disease. The Tacrine Collaborative Study Group. *N. Engl. J. Med.* 1992, 327, 1253–1259. [CrossRef]

300. Wood, P.C.; Castleden, C.M. A double-blind, placebo-controlled, multicentre study of tacrine for Alzheimer’s disease. *Int. J. Geriatr. Psychiatry* 1994, 9, 649–654. [CrossRef]

301. Azmi, A.S. Adopting network pharmacology for cancer drug discovery. *Curr. Drug Discov. Technol.* 2013, 10, 95–105. [CrossRef]

302. Li, P.; Fu, Y.; Wang, Y. Network based approach to drug discovery: A mini review. *Mini Rev. Med. Chem.* 2015, 15, 687–695. [CrossRef]

303. Chandra, N.; Padiadpu, J. Network approaches to drug discovery. *Expert Opin. Drug Discov.* 2013, 8, 7–20. [CrossRef]

304. Zhou, J.; Seeley, W.W. Network dysfunction in Alzheimer’s disease and frontotemporal dementia: Implications for psychiatry. *Biol. Psychiatry* 2014, 75, 565–573. [CrossRef] [PubMed]

305. Thal, L.J.; Kantarcı, K.; Reiman, E.M.; Klunk, W.E.; Weiner, M.W.; Zetterberg, H.; Galasko, D.; Praticò, D.; Griffin, S.; Schenk, D.; et al. The role of biomarkers in clinical trials for Alzheimer disease. *Alzheimer Dis. Assoc. Disord.* 2006, 20, 6–15. [CrossRef] [PubMed]

306. Brodney, M.A.; Beck, E.M.; Butler, C.R.; Barreiro, G.; Johnson, E.F.; Riddell, D.; Parris, K.; Nolan, C.E.; Fan, Y.; Atchison, K. Utilizing structures of CYP2D6 and BACE1 complexes to reduce risk of drug–drug interactions with a novel series of centrally efficacious BACE1 inhibitors. *J. Med. Chem.* 2015, 58, 3223–3252. [CrossRef] [PubMed]

307. Atri, A.; Molinuevo, J.L.; Lemming, O.; Wirth, Y.; Puls, I.; Wilkinson, D. Memantine in patients with Alzheimer’s disease receiving donepezil: New analyses of efficacy and safety for combination therapy. *Alzheimer Res. Ther.* 2013, 5, 1–11. [CrossRef]

308. Hopkins, A.L. Network pharmacology: The next paradigm in drug discovery. *Nat. Chem. Biol.* 2008, 4, 682–690. [CrossRef]

309. Bolognesi, M.L. Polypharmacology in a single drug: Multitarget drugs. *Curr. Drug Discov. Technol.* 2014, 11, 10773–10778. [CrossRef]

310. Zhao, B.; Hemann, M.T.; Lauffenburger, D.A. Intratumor heterogeneity alters most effective drugs in designed combinations. *Proc. Natl. Acad. Sci. USA* 2014, 111, 10773–10778. [CrossRef]

311. Viana, E.; Sola, I.; Di Pietro, O.; Munoz-Torero, D. Human disease and drug pharmacology, complex as real life. *Curr. Med. Chem.* 2013, 20, 1623–1634. [CrossRef]

312. Zhang, H.; Zhang, Y.; Li, Y.; Wang, Y.; Yan, S.; Xu, S.; Deng, Z.; Yang, X.; Xie, H.; Li, J. Bioinformatics and Network Pharmacology Identify the Therapeutic Role and Potential Mechanism of Melatonin in AD and Rosacea. *Front. Immunol.* 2021, 12, 756550. [CrossRef]

313. Barabási, A.L.; Gulbahce, N.; Loscalzo, J. Network medicine: A network-based approach to human disease. *Nat. Rev. Genet.* 2011, 12, 56–68. [CrossRef] [PubMed]

314. Sonawane, A.R.; Weiss, S.T.; Glass, K.; Sharma, A. Network Medicine in the Age of Biomedical Big Data. *Front. Genet.* 2019, 10, 294. [CrossRef]

315. Zhang, Z.; Yi, P.; Yang, J.; Huang, J.; Xu, P.; Hu, M.; Zhang, C.; Wang, B.; Peng, W. Integrated network pharmacology analysis and serum metabolomics to reveal the cognitive improvement effect of Bushen Tiansui formula on Alzheimer’s disease. *J. Ethnopharmacol.* 2020, 249, 112371. [CrossRef] [PubMed]

316. Kitano, H. A robustness-based approach to systems-oriented drug design. *Nat. Rev. Drug Discov.* 2007, 6, 202–210. [CrossRef] [PubMed]

317. Umar, T.; Hoda, N. Alzheimer’s Disease: A Systemic Review of Substantial Therapeutic Targets and the Leading Multi-functional Molecules. *Curr. Top. Med. Chem.* 2017, 17, 3370–3389. [CrossRef]

318. Oset-Gasque, M.J.; Marco-Contelles, J. Alzheimer’s Disease, the “One-Molecule, One-Target” Paradigm, and the Multitarget Directed Ligand Approach. *ACS Chem. Neurosci.* 2018, 9, 401–403. [CrossRef] [PubMed]

319. Agis-Torres, A.; Söllhuber, M.; Fernandez, M.; Sanchez-Montero, J.M. Multi-Target-Directed Ligands and other Therapeutic Strategies in the Search for a Real Solution for Alzheimer’s Disease. *Curr. Neuropharmacol.* 2014, 12, 2–36. [CrossRef] [PubMed]
Diagnostics 2022, 12, 2975

321. Wang, T.; Liu, X.H.; Guan, J.; Ge, S.; Wu, M.B.; Lin, J.P.; Yang, L.R. Advancement of multi-target drug discoveries and promising applications in the field of Alzheimer’s disease. *Eur. J. Med. Chem.* 2019, 169, 200–223. [CrossRef] [PubMed]

322. Alcaro, S.; Bolognesi, M.L.; García-Sosa, A.T.; Rapposelli, S. Editorial: Multi-Target-Directed Ligands (MTDL) as Challenging Research Tools in Drug Discovery: From Design to Pharmacological Evaluation. *Front. Chem.* 2019, 7, 71. [CrossRef]

323. Kumar, N.; Kumar, V.; Anand, P.; Kumar, V.; Ranjan Dwivedi, A.; Kumar, V. Advancements in the development of multi-target directed ligands for the treatment of Alzheimer’s disease. *Bioorg. Med. Chem.* 2022, 61, 116742. [CrossRef]

324. Cavalli, A.; Bolognesi, M.L.; Minarini, A.; Rosini, M.; Tumiatti, V.; Recanatini, M.; Melchiorre, C. Multi-target-directed ligands to combat neurodegenerative diseases. *J. Med. Chem.* 2008, 51, 347–372. [CrossRef] [PubMed]

325. Kabir, M.T.; Uddin, M.S.; Mamun, A.A.; Jeandet, P.; Aleya, L.; Mansouri, R.A.; Mathew, B.; Bin-Jumah, M.N.; Abdel-Daim, M.M. Combination Drug Therapy for the Management of Alzheimer’s Disease. *Int. J. Mol. Sci.* 2020, 21, 3272. [CrossRef] [PubMed]

326. Benchekroun, M.; Maramai, S. Multitarget-directed ligands for neurodegenerative diseases: Real opportunity or blurry mirage? *Future Med. Chem.* 2019, 11, 261–263. [CrossRef]

327. Ramsay, R.R.; Majekova, M.; Medina, M.; Valoti, M. Key Targets for Multi-Target Ligands Designed to Combat Neurodegeneration. *Front. Neurosci.* 2016, 10, 375. [CrossRef] [PubMed]

328. Benedek, O.; Korabecny, J.; Soukup, O. A perspective on multi-target drugs for Alzheimer’s disease. *Trends Pharmacol. Sci.* 2020, 41, 434–445. [CrossRef] [PubMed]

329. Haass, C.; Selkoe, D.J. Soluble protein oligomers in neurodegeneration: Lessons from the Alzheimer’s amyloid β-peptide. *Nat. Rev. Mol. Cell Biol.* 2007, 8, 101–112. [CrossRef] [PubMed]

330. Eisenberg, D.; Jucker, M. The amyloid state of proteins in human diseases. *Nat. Rev. Mol. Cell Biol.* 2012, 13, 1167–1203. [CrossRef]

331. Knowles, T.P.; Vendruscolo, M.; Dobson, C.M. The amyloid state and its association with protein misfolding diseases. *Nat. Rev. Mol. Cell Biol.* 2014, 15, 384–396. [CrossRef] [PubMed]

332. LaFerla, F.M.; Green, K.N.; Oddo, S. Intracellular amyloid-β in Alzheimer’s disease. *Nat. Rev. Neurosci.* 2007, 8, 499–509. [CrossRef] [PubMed]

333. Hampel, H.; Hardy, J.; Blennow, K.; Chen, C.; Perry, G.; Kim, S.H.; Villemagne, V.L.; Aisen, P.; Vendruscolo, M.; Iwatsubo, T. The amyloid-β pathway in Alzheimer’s disease. *Mol. Psychiatry* 2012, 17, 5481–5503. [CrossRef] [PubMed]

334. Jadhav, S.; Avila, J.; Schöll, M.; Kovacs, G.G.; Kövári, E.; Skrabana, R.; Evans, L.D.; Kontsekova, E.; Malawksa, B.; De Silva, R. A walk through tau therapeutic strategies. *Acta Neuropathol. Commun.* 2019, 7, 1–31. [CrossRef] [PubMed]

335. Iqbal, K.; Liu, F.; Gong, C.-X. Recent developments with tau-based drug discovery. *Expert Opin. Drug Discov.* 2018, 13, 399–410. [CrossRef] [PubMed]

336. Ballatore, C.; Lee, V.M.-Y.; Trojanowski, J.Q. Tau-mediated neurodegeneration in Alzheimer’s disease and related disorders. *Nat. Rev. Neurosci.* 2007, 8, 663–672. [CrossRef] [PubMed]

337. De Calignon, A.; Polydoro, M.; Suárez-Calvet, M.; Williams, C.; Adamowicz, D.H.; Kopeikina, K.J.; Pitstick, R.; Sahara, N.; Ashe, K.H.; Carlson, G.A. Propagation of tau pathology in a model of early Alzheimer’s disease. *Neuron* 2012, 73, 685–697. [CrossRef] [PubMed]

338. Hampel, H.; Mesulam, M.-M.; Cuello, A.C.; Khachaturian, A.S.; Vergallo, A.; Farlow, M.; Snyder, P.; Giacobini, E.; Khachaturian, Z. Revisiting the cholinergic hypothesis in Alzheimer’s disease: Emerging evidence from translational and clinical research. *J. Prev. Alzheimers Dis.* 2019, 6, 2–15. [CrossRef] [PubMed]

339. Gauthier, S.; Herrmann, N.; Rosa-Neto, P. Optimal use of cholinergic drugs in Alzheimer’s disease. *Brain* 2018, 141, e68. [CrossRef]

340. Balez, R.; Ooi, L. Getting to NO Alzheimer’s disease: Neuroprotection versus neurotoxicity mediated by nitric oxide. *Oxidative Med. Cell. Longev.* 2016, 2016, 3806157. [CrossRef] [PubMed]

341. Malinski, T. Nitric oxide and nitrooxidative stress in Alzheimer’s disease. *J. Alzheimer Dis.* 2007, 11, 207–218. [CrossRef] [PubMed]

342. Zádori, D.; Veres, G.; Szalárdy, L.; Klivényi, P.; Vécsei, L. Alzheimer’s disease: Recent concepts on the relation of mitochondrial disturbances, excitotoxicity, neuroinflammation, and kynurenines. *J. Alzheimer Dis.* 2018, 62, 523–547. [CrossRef] [PubMed]

343. Van Giua, V.; An, S.S.A.; Hulme, J.P. Mitochondrial therapeutic interventions in Alzheimer’s disease. *J. Neurol. Sci.* 2018, 395, 62–70. [CrossRef] [PubMed]

344. Swerdlow, R.H. Mitochondria and Mitochondrial Cascades in Alzheimer’s Disease. *J. Alzheimers Dis.* 2018, 62, 1403–1416. [CrossRef] [PubMed]

345. Magi, S.; Castaldo, P.; Macri, M.L.; Maiolino, M.; Matteucci, A.; Bastioli, G.; Gratteri, S.; Amoroso, S.; Lariocca, V. Intracellular Calcium Dysregulation: Implications for Alzheimer’s Disease. *Biomed. Res. Int.* 2016, 2016, 6701324. [CrossRef] [PubMed]

346. Calvo-Rodríguez, M.; Baeskai, B.J. Mitochondria and Calcium in Alzheimer’s Disease: From Cell Signaling to Neuronal Cell Death. *Trends Neurosci.* 2021, 44, 136–151. [CrossRef] [PubMed]

347. Vogler, E.C.; Bucsigligo, J. Disruption of zinc neuromodulation by Aβ oligomers: Therapeutic implications. *Curr. Pharm. Des.* 2014, 20, 2520–2524. [CrossRef] [PubMed]

348. Serrano-Pozo, A.; Das, S.; Hyman, B.T. APOE and Alzheimer’s disease: Advances in genetics, pathophysiology, and therapeutic approaches. *Lancet Neurol.* 2021, 20, 68–80. [CrossRef] [PubMed]

349. Lanfranco, M.F.; Ng, C.A.; Rebeck, G.W. ApoE Lipidation as a Therapeutic Target in Alzheimer’s Disease. *Int. J. Mol. Sci.* 2020, 21, 6336. [CrossRef] [PubMed]
350. Roessler, H.J.; Knoers, N.; van Haelst, M.M.; van Haften, G. Drug Repurposing for Rare Diseases. *Trends Pharmacol. Sci.* 2021, 42, 255–267. [CrossRef]

351. Pushpakom, S.; Iorio, F.; Eyers, P.A.; Escott, K.J.; Hopper, S.; Wells, A.; Doig, A.; Guilliams, T.; Latimer, J.; McNamee, C.; et al. Drug repurposing: Progress, challenges and recommendations. *Nat. Rev. Drug Discov.* 2019, 18, 41–58. [CrossRef]

352. Cha, Y.; Erez, T.; Reynolds, I.J.; Kumar, D.; Ross, J.; Koytiger, G.; Kusko, R.; Zaskind, B.; Risso, S.; Kagan, E.; et al. Drug repurposing from the perspective of pharmaceutical companies. *Br. J. Pharmacol.* 2018, 175, 168–180. [CrossRef]

353. Hajo, R.; Setola, V.; Roth, B.L.; Tropsha, A. Chemocentric informatics approach to drug discovery: Identification and experimental validation of selective estrogen receptor modulators as ligands of 5-hydroxytryptamine-6 receptors and as potential cognition enhancers. *J. Med. Chem.* 2012, 55, 5704–5719. [CrossRef]

354. Morphy, R.; Rankovic, Z. Designing multiple ligands—medicinal chemistry strategies and challenges. *Curr. Pharm. Des.* 2009, 15, 587–600. [CrossRef] [PubMed]

355. Rankovic, Z. CNS drug design: Balancing physicochemical properties for optimal brain exposure. *J. Med. Chem.* 2015, 58, 2584–2608. [CrossRef] [PubMed]

356. Reichel, A. Addressing central nervous system (CNS) penetration in drug discovery: Basics and implications of the evolving new concept. *Chem. Biodivers.* 2009, 6, 2030–2049. [CrossRef] [PubMed]

357. Schneider, P.; Schneider, G. Privileged Structures Revisited. *Angew. Chem. Int. Ed. Engl.* 2017, 56, 7971–7974. [CrossRef]

358. Skoreński, M.; Sierczczyk, M. The Fellowship of Privileged Scaffolds-One Structure to Inhibit Them All. *Pharmaceuticals* 2021, 14, 1164. [CrossRef]

359. Zhao, H.; Dietrich, J. Privileged scaffolds in lead generation. *Expert Opin. Drug Discov.* 2015, 10, 781–790. [CrossRef]

360. Davison, E.K.; Bramble, M.A. Natural product derived privileged scaffolds in drug discovery. *Curr. Opin. Chem. Biol.* 2019, 52, 1–8. [CrossRef]

361. Duan, Y.; Zhu, H.L. Privileged Scaffolds for Drug Design and Activity Improvement-Part I. *Curr. Top. Med. Chem.* 2020, 20, 2519. [CrossRef]

362. Sun, D.; Gündisch, D. Privileged Scaffolds in Natural Products and Drug Discovery. *Curr. Top. Med. Chem.* 2016, 16, 1199. [CrossRef]

363. Hann, M.M.; Leach, A.R.; Harper, G. Molecular complexity and its impact on the probability of finding leads for drug discovery. *J. Chem. Inf. Comput. Sci.* 2001, 41, 856–864. [CrossRef]

364. Paul, D.; Sanap, G.; Shenoy, S.; Kalyane, D.; Kalia, K.; Tekade, R.K. Artificial intelligence in drug discovery and development. *Drug Discov. Today* 2021, 26, 80–93. [CrossRef] [PubMed]

365. Thomford, N.E.; Senthebeane, D.A.; Rowe, A.; Munro, D.; Seele, P.; Maroyi, A.; Dzobo, K. Natural Products for Drug Discovery in the 21st Century: Innovations for Novel Drug Discovery. *Int. J. Mol. Sci.* 2018, 19, 1578. [CrossRef]

366. Elahi, F.M.; Casaletto, K.B.; La Joie, R.; Walters, S.M.; Harvey, D.; Wolf, A.; Edwards, L.; Rivera-Contreras, W.; Karydas, A.; Cobigo, Y.; et al. Plasma biomarkers of astrocytic and neuronal dysfunction in early- and late-onset Alzheimer’s disease. *Alzheimers Dement.* 2020, 16, 681–695. [CrossRef] [PubMed]

367. Guidi, J.; Lucente, M.; Sonino, N.; Fava, G.A. Allostatic Load and Its Impact on Health: A Systematic Review. *Psychosom. Psychosom.* 2021, 90, 11–27. [CrossRef]

368. Nikolac Perkovic, M.; Sagud, M.; Tudor, L.; Konjevod, M.; Svob Strac, D.; Pivac, N. A Load to Find Clinically Useful Biomarkers for Depression. *Adv. Exp. Med. Biol.* 2021, 1305, 175–202. [CrossRef] [PubMed]

369. Richards, B.A.; Lillcrap, T.P.; Beaudoin, P.; Bengio, Y.; Bogacz, R.; Christensen, A.; Clopath, C.; Costa, R.P.; de Berker, A.; Ganguli, S.; et al. A deep learning framework for neuroscience. *Nat. Neurosci.* 2019, 22, 1761–1770. [CrossRef] [PubMed]

370. Mohammed, I.A. Artificial Intelligence for Caregivers of Persons with Alzheimer’s Disease and Related Dementias: Systematic Literature Review. *J. Emerg. Technol. Innov. Res.* 2019, 2349, 741–744.

371. Hajo, R.; Sabbah, D.A.; Bardaweel, S.K.; Tropsha, A. Identification of Tumor-Specific MRI Biomarkers Using Machine Learning (ML). *Diagnoses* 2021, 11, 742. [CrossRef] [PubMed]

372. Fabrizio, C.; Termine, A.; Callagtrone, C.; Sancesario, G. Artificial Intelligence for Alzheimer’s Disease: Promise or Challenge? *Diagnoses* 2021, 11, 1473. [CrossRef]

373. Umeda-Kameyama, Y.; Kameyama, M.; Tanaka, T.; Son, B.-K.; Kojima, T.; Fukasawa, M.; Iizuka, T.; Ogawa, S.; Iijima, K.; Akishita, M. Screening of Alzheimer’s disease by facial complexion using artificial intelligence. *Aging Dis.* 2021, 12, 1014–1021. [CrossRef] [PubMed]

374. Geerts, H.; Dacks, P.A.; Devanarayan, V.; Haas, M.; Khachatourian, Z.S.; Gordon, M.F.; Maudsley, S.; Romero, K.; Stephenson, D.; Initiative, B.H.M. Big data to smart data in Alzheimer’s disease: The brain health modeling initiative to foster actionable knowledge. *Alzheimers Dement.* 2016, 12, 1014–1021. [CrossRef] [PubMed]

375. Gunning, D.; Stefik, M.; Choi, J.; Miller, T.; Stumpf, S.; Yang, G.Z. XAI-Explainable artificial intelligence. *Sci. Robot.* 2019, 4. [CrossRef] [PubMed]

376. Mishra, R.; Li, B. The Application of Artificial Intelligence in the Genetic Study of Alzheimer’s Disease. *Aging Dis.* 2020, 11, 1567–1584. [CrossRef] [PubMed]

377. El-Sappagh, S.; Alonso, J.M.; Islam, S.; Sultan, A.M.; Kwak, K.S. A multilayer multimodal detection and prediction model based on explainable artificial intelligence for Alzheimer’s disease. *Sci. Rep.* 2021, 11, 2660. [CrossRef]

378. Carpenter, K.A.; Huang, X. Machine learning-based virtual screening and its applications to Alzheimer’s drug discovery: A review. *Curr. Pharm. Des.* 2018, 24, 3347–3358. [CrossRef]
407. Kwon, D.Y.; Zhao, Y.T.; Lamonica, J.M.; Zhou, Z. Locus-specific histone deacetylation using a synthetic CRISPR-Cas9-based HDAC. Nat. Commun. 2017, 8, 15315. [CrossRef] [PubMed]

408. WHO. Risk Reduction of Cognitive Decline and Dementia: WHO Guidelines 2019. Available online: https://www.who.int/publications/i/item/risk-reduction-of-cognitive-decline-and-dementia (accessed on 20 October 2022).

409. Bukhbinder, A.S.; Ling, Y.; Hasan, O.; Jiang, X.; Kim, Y.; Johner, C.; Wekerle, H.; Krishnamoorthy, G. Commensal microbiota and myelin autoantigen cooperate to trigger autoimmune demyelination. Nature 2011, 479, 538–541. [CrossRef]

410. Clemente, J.C.; Ursell, L.K.; Parfrey, L.W.; Knight, R. The impact of the gut microbiota on human health: An integrative view. Cell 2012, 148, 1258–1270. [CrossRef]

411. Berer, K.; Mues, M.; Koutrotsos, M.; Rasbi, Z.A.; Boziki, M.; Johner, C.; Wekerle, H.; Krishnamoorthy, G. Commensal microbiota and myelin autoantigen cooperate to trigger autoimmune demyelination. Nature 2011, 479, 538–541. [CrossRef]

412. Cattaneo, A.; Cattane, N.; Galluzzi, S.; Provasi, S.; Lopizzo, N.; Festari, C.; Ferrari, C.; Guerra, U.P.; Paghera, B.; Muscio, C.; et al. Association of brain amyloidosis with pro-inflammatory gut bacterial taxa and peripheral inflammation markers in cognitively impaired elderly. Neurobiol. Aging 2017, 49, 60–68. [CrossRef]

413. Keshavarzian, A.; Green, S.J.; Engen, P.A.; Voigt, R.M.; Naqib, A.; Forsyth, C.B.; Mutlu, E.; Shannon, K.M. Colonic bacterial composition in Parkinson’s disease. Mov. Disord. 2015, 30, 1351–1360. [CrossRef]

414. Vogt, N.M.; Kerby, R.L.; Dill-McFarland, K.A.; Harding, S.J.; Merluzzi, A.P.; Johnson, S.C.; Carlsson, C.M.; Asthana, S.; Zetterberg, H.; Blennow, K.; et al. Gut microbiome alterations in Alzheimer’s disease. Sci. Rep. 2017, 7, 13537. [CrossRef]

415. Askarova, S.; Umbayev, B.; Masoud, A.R.; Kaiyrlykyzy, A.; Safarova, Y.; Tsoy, A.; Olzhayev, F.; Kushugulova, A. The Links Between the Gut Microbiome, Aging, Modern Lifestyle and Alzheimer’s Disease. Front. Cell. Infect. Microbiol. 2020, 10, 104. [CrossRef] [PubMed]

416. Angelucci, F.; Cechova, K.; Amlerova, J.; Hort, J. Antibiotics, gut microbiota, and Alzheimer’s disease. J. Neuroinflamm. 2019, 16, 108. [CrossRef] [PubMed]

417. Lin, L.; Zheng, L.J.; Zhang, L.J. Neuroinflammation, Gut Microbiome, and Alzheimer’s Disease. Mol. Neurobiol. 2018, 55, 8243–8250. [CrossRef]

418. Jiang, C.; Li, G.; Huang, P.; Liu, Z.; Zhao, B. The Gut Microbiota and Alzheimer’s Disease. J. Alzheimers Dis. 2017, 58, 1–15. [CrossRef] [PubMed]

419. Nagpal, R.; Neth, B.J.; Wang, S.; Craft, S.; Yadav, H. Modified Mediterranean-ketogenic diet modulates gut microbiome and short-chain fatty acids in association with Alzheimer’s disease markers in subjects with mild cognitive impairment. EBioMedicine 2019, 47, 529–542. [CrossRef]

420. MahmoudianDehkordi, S.; Arnold, M.; Nho, K.; Ahmad, S.; Jia, W.; Xie, G.; Louie, G.; Kueider-Paisley, A.; Moseley, M.A.; Thompson, J.W.; et al. Altered bile acid profile associates with cognitive impairment in Alzheimer’s disease-An emerging role for gut microbiome. Alzheimers Dement. 2019, 15, 76–92. [CrossRef] [PubMed]

421. Sochocka, M.; Donskow-Lysoniewska, K.; Diniz, B.S.; Kupas, D.; Brzozowska, E.; Leszek, J. The Gut Microbiome Alterations and Inflammation-Driven Pathogenesis of Alzheimer’s Disease-a Critical Review. Mol. Neurobiol. 2019, 56, 1841–1851. [CrossRef]

422. Harach, T.; Marungruang, N.; Duthilleul, N.; Cheatham, V.; Mc Coy, K.D.; Frisoni, G.; Neher, J.J.; Fäk, F.; Jucker, M.; Lasser, T.; et al. Reduction of Abeta amyloid pathology in APPPS1 transgenic mice in the absence of gut microbiota. Sci. Rep. 2017, 7, 41802. [CrossRef]

423. An, M.W.; Duong, Q.; Le-Rademacher, J.; Mandrekar, S.J. Principles of Good Clinical Trial Design. J. Thorac. Oncol. 2020, 15, 1277–1280. [CrossRef]

424. Evans, S.R. Fundamentals of clinical trial design. J. Exp. Stroke Transl. Med. 2010, 3, 19–27. [CrossRef]

425. Schindler, R.J. Study design considerations: Conducting global clinical trials in early Alzheimer’s disease. J. Nutr. Health Aging 2010, 14, 312–314. [CrossRef] [PubMed]

426. Cummings, J.; Gould, H.; Zhong, K. Advances in designs for Alzheimer’s disease clinical trials. Am. J. Neurodegener. Dis. 2012, 1, 205–216. [PubMed]